1. No category

First International Convention
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
III International Congress on Immunopharmacology
(IMMUNOPHARMACOLOGY 2015)
III International Congress on Pharmacology of
Vaccines
(VACCIPHARMA 2015)
SCIENTIFIC PROGRAM
Cuban Society of Pharmacology
Meliá Marina Varadero, Varadero Beach, Cuba
June 14-19, 2015
http://www
.imm
uno
vaccipharmacuba.com
http://www.imm
.immuno
unov
The International Union of Basic and Clinical Pharmacology (IUPHAR), The IUPHAR Section of
Immunopharmacology and the Cuban Society of Pharmacology are organizing the First International
Convention IMMUNOPHARMACOLOGY–VACCIPHARMA 2015, scheduled for June 14-19, 2015 at
the Meliá Marina Varadero Hotel, in Varadero beach, Cuba. This Convention is the fusion of the 3rd
International Congress on Immunopharmacology (IMMUNOPHARMACOLOGY 2015) and the 3rd
International Congress on Pharmacology of Vaccines (VACCIPHARMA 2015)
The key objectives of the Convention are:
♦ To provide a progressive state-of-the-art report for scientists, manufacturers, regulators and
healthcare workers in the fields of immunological research and the development and research
on vaccines.
♦ To promote the experience exchange, the presentation of results and the discussion on topics
related with the activities scheduled, as well as creating a suitable framework for collaboration.
♦ To contribute to the acceptance of new products, methods and technologies.
Convention Organizers
Main Organizers:
International Union of Basic and Clinical Pharmacology (IUPHAR)
IUPHAR Section of Immunopharmacology
Latin-American Association of Pharmacology (ALF)
Cuban Society of Pharmacology (SCF)
Local co-organizers:
Cuban National Council of Health Scientific Societies
Cuban Society of Parasitology and Microbiology
Finlay Institute
Centre for Genetic Engineering and Biotechnology (CIGB)
Centre of Molecular Immunology (CIM)
International Center for Neurological Restoration (CIREN)
Finlay Editions
State Centre for Control of Drugs, Equipment and Medical Devices (CECMED)
LABIOFAM
Tropical Medicine Institute (IPK)
CIDEM
CEBIMAR
CENSA
BioCEN
Centre for the Research and Rehabilitation of Hereditary Ataxias (CIRAH)
Convention sponsors:
Pan-American Health Organization (PAHO)
PNUD
IBRO
ROCHE
MERCK
SARTORIUS
RS-IMEX
IBS
SEPPIC
BDC
ABIVAX
NUOVA OMPI
KARL STORZ
IBADECAM
BRAUN
DIAGNOVUM
BLANC-LABO
COPA AIRLINES
CONFITERÍA Y DERIVADOS DE LA HARINA
Or
ganizing Committee
Org
President: Mario Landys Chovel Cuervo
Finlay Institute / SCF
Silvio E. Perea
CIGB
Idania Rodeiro
CEBIMAR
Reinaldo Acevedo
Finlay Institute
Ana María Vázquez
CIM
Néstor Expósito
CIGB
Ana María Hernández
CIM
Miladys Limonta
CIGB
Daniel Cardoso
Finlay Institute
Giset Jiménez
CECMED
Mabel Izquierdo
CIGB
René Delgado
CIDEM/President, SCF
María de los Ángeles Robinson
CIREN
Rolando Ochoa
Finlay Institute
Diadelis Remírez
CECMED
Eduardo Martínez
CIGB
Adamelis Avilés
CECMED
Luis García
Finlay Institute
Nadine Álvarez
Finlay Institute
Gillian Martínez
CIGB
Yanet Hechavarría
CECMED
Carmen Portuondo
CECMED
Sonia Resik
IPK
Giselle Pentón
CIGB
Shirley González
LABIOFAM
María Cristina Lara
MINSAP
Lizet Gil
IPK
Vilcy Reyes
CIGB
Liván Delgado
CEBIMAR
Dionisio Zaldívar
BIOMAT
Nely Rodríguez Zhurbenko
CIM
Narjara González
CIM
Vivian Kourí
IPK
Roberto Rodríguez
CIRAH
Beatriz Garrido
CIDEM
Alexis Labrada
BioCEN
Indira Utria
CQB
Scientif
ic Ad
visor
y Committee
Scientific
Advisor
visory
Presidents: Silvio E. Perea (CIGB) and Deybis Orta (CECMED )
Agustín Lage
CIM, Cuba
Angus Dagleish
John Hopkins Hospital, UK
Francesca Levi-Schaffer
The Hebrew University of
Jerusalem, Israel
Dorothea Sesardic
NIBSC, UK
Coenraad Hendriksen
Intravacc, The Netherlands
Micheline Piquette
Toronto University, Canada
Gustavo Sierra
OSDE, Cuba
Luis Herrera
CIGB, Cuba
Rafael Pérez Cristiá
CECMED, Cuba
Rolando Ochoa
Finlay Institute, Cuba
Ali Harandi
University of Gottemnburg, Sweden
Adrian Llerena
Extremadura University, Spain
Idania Rodeiro
CEBIMAR, Cuba
Dr. Uwe Gottschalk
Sartorius Stedim Biotech,
Germany
John Hiscott
McGill University, Montreal,
Canada
Wilson Savino
International Society of
Neuroimmunomodulation
(ISNIM), Brazil
Liliana Francis Turner,
Tolima University, Colombia
Dario Siniscalco
University of Naples, Italy
Hartmut Wekerle
ISNI, Germany
Carlos Alberto
Gonçalvez
UFRGS, Bra zil
Gianvito Martino
Italy
Rachel Tyndale
Canada
Valerie A. Ferro
University of Strahclyde, Scotland, UK
Bruce Levy
Harvard Medical School, USA
Alberto Mantovani
Institute Mario Neri, Milán,
Italy
Jorge Pérez
IPK, Cuba
Herve Bercovier
Hebrew University of
Jerusalem, Israel
María Guadalupe Guzmán
IPK, Cuba
Vicente Vérez
CQB, Cuba
Rino Rappuoli
Novartis, Italy
José Vicente Castell
Spain
Javier Espinosa
UNAM , Mexico
Carlo Riccardi
University of Perugia, Italy
Mauro Teixeira
University of Minas Gerais,
Brazil
Luis Velázquez Pérez
CIRAH, Cuba
Christopher Gomez
University of Chicago, USA
Ray Borrow
UK
Einar Rosenqvist
NIPH, Norway
Abraham Assefa
AHRI, Ethiopia
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
GENERAL PROGRAM / IMMUNOVACCIPHARMA 2015
Day / Hour
Sunday 14 /
09:00-14:00
Sunday 14 /
18:00-20:00
Monday 15 /
09:00-13:00
Monday 15 /
15:00-18:00
Tuesday 16 /
09:00-13:00
Tuesday 16 /
15:00-18:00
Wednesday 17 /
09:00-13:00
Wednesday 17 /
15:00-18:00
Room 1
Room 2
Room 3
Room 4
Room 5
Room 6
Room 7
Registration
Opening Ceremony and Plenary Lectures
WIP
VPL
SCP
WNI
SK
SIP
WIP
SMV
SCP
WNI
STBV
SVetV
WIP
SMV
WTV (1)
WNI
SAT
SBP
WIP
SEV
SCV (1)
WNI
SCTO
SPNV
WRS
WHIV
SAT
SBP
SPNV (RT)
WRS
SCV (3)
CPS
SBP
SHA
SBP
Wednesday 17 /
15:00-17:00
Poster presentations (Vaccines, Bioproc esses, Veterinary, AIDS and Regulatory System) /
Commercial Fair
Thursday 18 /
09:00-13:00
WTV (2)
(Ca ncer)
Poster presentations (Immunopharmacology, Pharmacology of Cytochrome P 450 ,
Neuroimmunology, Kinases, Inflammation and Pain , Atherosclerosis, Clinical and
Translational Oncology, Hereditary Ataxias ) / Commercial Fair
Thursday 18 /
15:00-17:00
Thursday 18 /
18:00-19:30
Thursday 18 /
20:00-01:00
Friday 19 /
9:00-12:00
SCTO
SVV
SCV (2)
Closing Ceremony
Dinner and Farewell Party
Exchanging among delegates
Legend:
WIP: Workshop Immunopharmacology;
SCTO:Symposium Clinical and Translational Oncology;
VPL: Vaccine Plenary Lectures;
SMV: Symposium Meningococcal Vaccines;
SEV: Symposium Enteric Vaccines
SPNV: Symposium Pneumococcal Vaccines;
SVV: Symposium Viral Vaccines;
SCP: Symposium Pharmacology of Cytochrome P 450,
Transporters and OMICS;
WTV: Workshop Therapeutic Vaccines
(1. Infectious diseases);
SCV: Symposium Combined Vaccines
(1. Polio Vaccines);
WRS: Workshop Regulatory System;
SVC: Symposium Combined Vaccines
(2. Pertussis Vaccines);
WNI: Workshop Neuroimmunology;
WVIH: Workshop VIH-AIDS;
SCV: Symposium Combined Vaccines
(3. D-T-P-IPV-HB-Hib);
WTV: Workshop Therapeutic Vaccines
(2. Cancer)
SK:
Symposium Kinases;
STBV: Symposium Tuberculosis Vaccines;
SAT: Symposium Atherosclerosis;
CPS: Commercial Presentations Session
SIP: Symposium Inflammation and Pain
SVetV:Symposium Veterinary Vaccines
SBP: Symposium Bioprocesses;
SHA: Symposium Hereditary Ataxias
Other activities:
Room 7, Tuesday 16, 18:00-20:00: IUPHAR-ALF-Cuban Society of Pharmacology Meeting.
Note 1: Coffe Breaks will be into the rooms during the morning time.
Note 2: Lunches will be held from Monday to Friday, 13:00-15:00 hours.
6
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
GENERAL PROGRAM
PLENARY LECTURES SESSION (PLENARY ROOM)
SUNDAY 14 (18:00-20:30)
18:45-19:25 CHANGING VIEWS IN THE IMMUNOLOGY OF VACCINATION AND THE CHALLENGES AHEAD
(Shiv Pillai, Harvard Medical School Cambridge, PA. USA)
19:30-20:10 IMMUNOTHERAPY AS AN EMERGING PARADIGM IN ADVANCED CERVICAL CANCER
(Tewari Krishnansu, Todd cancer Pavilion, Long Beach, CA, USA)
IMMUNOPHARMACOLOGY SYMPOSIUM (ROOM 1)
MONDAY 15 (09:00-13:05)
Topic: B cell function and regulation: impact of aging
Chairs: Thomas Rothstein (USA)/Ana M Hernández (CUBA)
09:00-09:30 B LYMPHOCYTE SELECTION AND HOMEOSTASIS (Michael Cancro, University of
Pennsylvania, PA, USA)
09:35-10:05 THE HUMAN COUNTERPART OF MOUSE B-1 CELLS (Thomas Rothstein, The Feinstein
Institute for Medical Research, NY, USA)
10:10-10:30 HUMAN B-1 AND B-2 CELLS ARE GENERATED FROM A COMMON UMBILICAL CORD BLOOD
PROGENITOR CD34+CD38LO/INT CELL POPULATION (Tam D Quach, The Feinstein Institute for Medical
Research, NY, USA)
10:35-11:05 PROTECTIVE NATURAL AUTOANTIBODIES TO APOPTOTIC CELLS: EVIDENCES OF
CONVERGENT SELECTION OF RECURRENT INNATE-LIKE CLONES (Gregg Silverman, NY Univ School of
Medicine, NY, USA)
11:10-11:30 CHARACTERIZATION OF B AND T CELLS INVOLVED IN IMMUNOGENIC PROPERTIES OF
ANTI-IDIOTYPIC ANTIBODY (Darel Martinez, Center of Molecular Immunology, Havana, Cuba)
11:30-11:45 COFFEE BREAK
Chairs: Bonnie B Blomberg (USA)/ Gregg Silverman (USA)
11:45-12:15 BIOMARKERS FOR HUMAN VACCINE RESPONSE WHICH CHANGE WITH AGE: B CELL
SUBSETS, AID, MIRS, INFLAMMATION, AND CMV (Bonnie B Blomberg, Univ of Miami, FLA, USA)
12:20-12:40 NATURAL CYTOTOXIC ANTIBODIES AGAINST TUMOR NEUGCGM3 GANGLIOSIDE DECREASE
WITH AGE AND ARE ABSENT IN NSCLC PATIENTS (Nely Rodriguez-Zhurbenko, Center of Molecular
Immunology, Cuba)
7
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
12:45-13:05 AGE-RELATED DECLINE IN NATURAL IGM FUNCTION: DIVERSIFICATION AND SELECTION
OF THE B-1A CELL POOL WITH AGE (Nichole Holodick, The Feinstein Institute for Medical Research, NY,
USA)
IMMUNOPHARMACOLOGY SYMPOSIUM (ROOM 1)
MONDAY 15 (15:00-17:35)
Topic: Immunomodulation
Chairs: Dirk Homann (USA)/Tania Carmenate (CUBA)
15:00-15:30 HOW AGING CAN IMPROVE IMMUNE PROTECTION: AN INTEGRATED PERSPECTIVE ON
THE TEMPORAL ORGANIZATION OF CD8+T CELL MEMORY (Dirk Homann, Mount Sinai Sch of Medicine,
NY, USA)
15:35-15:55 CELLULAR MECHANISMS INVOLVED IN MACROPHAGE ACTIVATION INDUCED BY THE
MUCOSAL ADJUVANT PROTOXIN CRY1AC (Damarys Ilhuicatzi, Universidad Nacional Autónoma de
México, Estado de Mexico, Mexico)
16:00-16:20 IMMUNOSTIMULATING EFFECTS OF CRY1AC TOXIN AND IDENTIFICATION OF PUTATIVE
RECEPTORS IN MURINE MACROPHAGES (Nestor Rubio-Infante, Laboratorio de Inmunidad en Mucosas,
México)
16:25-16:45 IN VITRO AND IN VIVO COMPARISON OF CD40, DEC-205, OR CD11C FOR TARGETING OF
NANOPARTICLES ON DENDRITIC CELLS FOR EFFICIENT INDUCTION OF CD8+ T CELL RESPONSE (Luis J
Cruz, Leiden University Medical Center, Leiden, The Netherlands)
16:50-17:10 TOWARDS A BETTER THERAPY BASED ON IL-2, AVOIDING TREG CELL EXPANSION (Tania
Carmenate, Center of Molecular Immunology, Havana, Cuba)
17:15-17:35 APL-1, A PEPTIDE AS IMMUNOMODULATOR FOR THE TREATMENT OF JUVENILE IDIOPATHIC
ARTHRITIS (Norailys Lorenzo, Center for Genetic Engineering & Biotechnology, Havana, CUBA)
IMMUNOPHARMACOLOGY SYMPOSIUM (ROOM 1)
TUESDAY 16 (09:00-13:15)
Topic: Relevant targets & translational research on inflammation
Chairs: Shiv Pillai (USA)/Patricia Hernandez (CUBA)
09:00-09:30 METABOLIC INHIBITORS TO TREAT LUPUS (LAURENCE M. MOREL, DEP OF MEDICINE
UNIVERSITY OF FLORIDA, GAINESVILLE, FL, USA)
8
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
09:35-09:55 TARGETING CD6 MODULATES INFLAMMATORY-MEDIATED PATHWAYS AND ACHIEVES
THERAPEUTIC RESPONSE IN AUTOIMMUNITY SETTING (Patricia Hernandez, Center of Molecular
Immunology, Havana, Cuba)
10:00-10:20 NOVEL IL15 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES (Jacques
Yannick, CRCNA, University of Nantes, Nantes, France)
10:25-10:45 VERY SMALL SIZE PROTEOLIPOSOMES ABROGATE CROSS-PRESENTATION OF TUMOR
ANTIGENS BY MYELOID-DERIVED SUPPRESSOR CELLS AND INDUCE THEIR DIFFERENTIATION TO
DENDRITIC CELLS (Odrey Fernandez, Center of Molecular Immunology, Havana, Cuba)
10:50-11:10 NEOPLASTIC TRANSFORMATION CAN CONCERTS IMMUNE EVASION AND INFLAMMATION
IN THE ABSENCE OF EXTRINSIC IMMUNE PRESSURE: LESSONS FROM A MODEL BASED ON
MESENCHYMAL STEM CELLS (Alex Miranda, Center of Molecular Immunology, Havana, Cuba)
11:15-11:30 COFFEE BREAK
Chairs: Jacques Yannick (France)/Alicia Santos (CUBA)
11:30-12:00 CD4+ CYTOLYTIC T CELLS: DRIVERS OF INFLAMMATORY FIBROSIS AND A LAYER OF HUMAN
ANTI-VIRAL PROTECTION (Shiv S. Pillai, Harvard Medical School Cambridge, MA, USA)
12:05-12:25 NO-HYBRIDIZED PROTEASE INHIBITORS AS NOVEL DRUGS FOR THE TREATMENT OF CANCER
AND AUTOIMMUNE DISEASES (Ferdinando Nicoletti, Dep of Biomedical and Biotechnological Sciences,
University of Catania, Italy)
12:30-12:50 ANTI-INFLAMMATORY ACTION OF GLUCOCORTICOIDS: ROLE OF GILZ (Carlo Riccardi,
Department of Medicine, University of Perugia, Perugia, Italy)
12:55-13:15 A NOVEL PEPTIDE SELECTED FROM AN ALA-SCANNING REGULATES THE ONCOGENICINFLAMMATORY ACTIVITY OF NFKB IN CANCER CELLS (BRIZAIDA OLIVA, CENTER FOR GENETIC
ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA)
IMMUNOPHARMACOLOGY SYMPOSIUM (ROOM 1)
TUESDAY 16 (15:00-18:00)
Topic: Immunopharmacology and Allergy
Chairs: Francesca Levi-Schaffer (Scotland) / Carlo Riccardi (Italy)
15:00-15:30 GLIAL CONTROL OF NEUROINFLAMMATION IN TRAUMATIC CENTRAL NERVOUS SYSTEM
INJURIES: ROLE OF FATTY ACID ETHANOL AMIDES (Salvatore Cuzzocrea, University of Messina, Italy)
15:35-16:05 ACTIVATION OF INHIBITORY RECEPTORS BY SPECIFIC ANTIBODIES AS A TREATMENT FOR
ALLERGIC DISEASES (Francesca Levi-Schaffer, Hebrew University of Jerusalem, Israel)
16:10-16:40 ANTI-INFLAMMATORY ACTION OF GLUCOCORTICOIDS: ROLE OF GILZ (Carlo Riccardi,
Department of Medicine, University of Perugia, Perugia, Italy)
9
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
16:45-17:15 HUMAN MONOCYTES AND MACROPHAGES FOR THE SENSITIVE AND ROBUST IN VITRO
EVALUATION OF IMMUNOMODULATORY AND IMMUNOTOXIC EFFECTS (Diana Boraschi, National
Research Council, Napoli, Italy)
17:20-17:50 SEEKING FOR IMMUNOLOGICAL MARKERS PREDICTING THE EFFICACY AND SAFETY OF
NOVEL ALLERGEN-SPECIFIC IMMUNOTHERAPY PRODUCTS (Alexis Labrada, BioCEN, Cuba)
IMMUNOPHARMACOLOGY SYMPOSIUM (ROOM 1)
WEDNESDAY 17 (09:00-13:25)
Topic: Translational & Clinical Oncology (I)
Chairs: Lesley A Stark (Scotland/ Kalet Leon (Cuba)
09:00-9:30 CK2 AS A CANCER BIOMARKER (Isabel Dominguez, Boston University School of Medicine,
Boston, MA, USA)
09:35-09:55 COMMD1 IN COLORECTAL CANCER PROGRESSION AND THE CHEMOPREVENTATIVE
EFFECTS OF ASPIRIN (Lesly A Stark, Edinburgh Cancer Research Centre, Institute of Genetics and
Molecular Medicine, Edinburgh, Scotland, UK)
10:00-10:20 RATIONAL DESIGN OF A TGFB1 MUTANT USEFUL FOR CANCER IMMUNOTHERAPY (Kalet
Leon, Center of Molecular Immunology, Havana, Cuba)
10:25-10:45 HUMAN THERAPEUTIC ENZYME SPECIFICALLY SABOTAGES TUMOR METABOLISM BY AN
ENGINEERED CYSTINE/CYSTEINE DEGRADING ACTIVITY (Shira Cramer, Dep of Biomedical and Chemical
Engineering, The Univ of Texas, Austin, TX, USA)
10:50-11:10 ECTOPIC MICRORNA-150-5P TRANSCRIPTION MIMICKS GLUCOCORTICOID THERAPY
RESPONSE IN MM1S MULTIPLE MYELOMA CELLS BUT FAILS TO OVERCOME HORMONE THERAPY
RESISTANCE IN MM1R CELLS (Wim Vanden Berghe, 2.
Lab of Eukaryotic Gene Expression and
Signal Transduction (LEGEST), Ghent University, Belgium)
11:15-11:30 COFFEE BREAK
Chairs: Wim Vanden Berghe (Belgium)/ Circe Mesa (Cuba)
11:30-12:00 NATURAL KILLER CELL LINE GENETICALLY MODIFIED WITH A CHIMERIC ANTIGEN RECEPTOR
(CAR) WITH SPECIFICITY AGAINST MALIGNANT TUMORS (Gabriele Percher, Charité – University
Medicine of Berlin, Berlin, Germany)
12:05-12.35 GENERATION AND FUNCTION OF ENGINEERED HUMAN REGULATORY T CELLS FOR
AUTOIMMUNITY: LESSONS FROM CAR THERAPY (David Scott, Dep of Med, Uniformed Services Univ of
the Health Sciences, Bethesda, MD, USA)
10
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
12:40-13:00 GANGLIOSIDE CONTAINING NANO-PROTEOLIPOSOME REDUCES NUMBER OF MYELOIDDERIVED SUPPRESSOR CELLS: FIRST CLINICAL EVIDENCES IN METASTATIC RENAL CANCER PATIENTS
(Circe Mesa, Center of Molecular Immunology, Havana, Cuba)
13:05-13:25 ANTITUMOR AND CYTOTOXIC PROPERTIES OF A HUMANIZED ANTIBODY SPECIFIC FOR
THE GM3 (NEU5GC) GANGLIOSIDE (Denise Dorvignit, Center of Molecular Immunology, Havana,
Cuba).
IMMUNOPHARMACOLOGY SYMPOSIUM (ROOM 1)
THURSDAY 18 (09:00-13:10)
Topic: Translational & Clinical Oncology (II)
Chairs: Rubén A Mesa (USA)/Leonardo Lami (Cuba)
09:00-09:20 FERTILITY PRESERVATION IN EARLY CERVICAL CANCER (Concepcion Diaz-Arrastia, BCM
Department of Ob/GynHouston, TX, USA)
09:25-09:45 SIGNIFICANT INCREASE OF OVERALL SURVIVAL AND CLINICAL IMMUNOLOGICAL RESPONSE
IN CANCER PATIENTS WITH CIGB-247 THERAPEUTIC VACCINE PREPARATION (Katty-Hind SelmanHousein, CIMEQ Hospital, Havana, CUBA)
09:50-10:10 EVOLVING TARGETED THERAPY FOR MYELOPROLIFERATIVE NEOPLASMS (Ruben A Mesa,
Mayo Clinic Cancer Center, AZ, USA)
10:15-10:35 NIMOTUZUMAB FOR THE TREATMENT OF CHILDREN WITH NEWLY DIAGNOSED DIFFUSE
INTRINSIC PONTINE GLIOMA (Camilo Rodriguez, Center of Molecular Immunology, Havana, CUBA)
10:40-11:00 EMERGING TARGETED THERAPIES AND THE ROLE OF IMMUNOTHERAPY IN CHRONIC
LYMPHOCYTIC LEUKEMIA (Jose F Leis, Mayo Clinic, AZ, USA)
11:00-11:15 COFFEE BREAK
Chairs: David Steensma (USA)/Jorge L Soriano (Cuba)
11:15-11:35 CIGB-128, NOVEL FORMULATION OF INTERFERONS (IFNS) WITH IMPROVED
PHARMACODYNAMICS FOR CANCER TREATMENT (Iraldo Bello, Center for Genetic Engineering and
Biotechnology, Havana, CUBA)
11:40-12:00 TREATMENT OF MYELODYSPLASTIC SYNDROMES (MDS) IN 2015 (David P. Steensma, DanaFarber Cancer Institute and Harvard Medical School, Boston, USA)
12:05-12:25 CURRENT BIOLOGICAL TARGETED AGENTS IN THE THERAPEUTIC OF COLORECTAL CANCER
(Leonardo Lami, National Institute of Oncology & Radiobiology, Havana, CUBA)
11
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
12:30-12:50 IDENTIFICATION AND CHARACTERIZATION OF LONG-TERM SURVIVAL POPULATION IN NONSMALL CELL LUNG CANCER PATIENTS TREATED WITH IMMUNOTHERAPIES (Patricia Lorenzo-Luaces,
Center of Molecular Immunology, Havana, CUBA)
12:50-13:10 RACOTUMOMAB-ALUM, NIMOTUZUMAB OR DOCETAXEL AS SWITCH MAINTENANCE
THERAPY FOR ADVANCED NSCLC: RANIDO TRIAL PRELIMINAR RESULTS (Maurenis Hernandez, Center
of Molecular Immunology, Cuba)
SYMPOSIUM ON PHARMACOLOGY OF CYTOCHROME P450,
TRANSPORTERS AND OMICS (ROOM 3)
MONDAY 15 (9:00-13:20)
Topics: Pharmacogenetic
Chairs: Adrián Llerena (Spain) / Howard L. McLeod (USA)
09:00-09:25 PHARMACOGENETICS IN IBERO AND LATIN-AMERICAN POPULATIONS (Adrián Llerena Ruiz,
Spain)
09:30-09:55 CLINICAL IMPLEMENTATION OF GENETIC TESTING IN MEDICINE (Lawrence Lesko, EU)
10:00-10:25 PERSONALIZED CANCER TREATMENT: SELECTING FROM A BASKET OF POTENTIAL
THERAPIES (Howard L. McLeod, USA)
10:30-10:45 FROM PHARMACOGENETICS TO PERSONALIZED MEDICINE: REGULATORY PERSPECTIVES
AND IMPLICATIONS FOR LATIN-AMERICAN COUNTRIES (Diadelis Remirez, Cuba)
10:50-11:05 FREQUENCY OF CYP2D6 POOR METABOLIZERS IN A SAMPLE OF CUBAN PATIENTS WITH
SCHIZOPHRENIA (Hilda Roblejo, Cuba)
11:10-11:35 Coffee break
Topics: OMICS
Chairs: Wim Vanden (Belgium) / Idania Rodeiro (Cuba)
11:35–12:00 EPIGENETIC RESPONSE OF DIETARY FLAVANOLS AND STEROIDAL WITH ANOLIDES IN
CHEMOPREVENTION OF CANCER-INFLAMMATION: FINDING THE NEEDLE IN THE HAYSTACK FOR
PERSONALIZED NUTRITIONAL RECOMMENDATIONS (Wim Vanden, Belgium)
12:05–12:30 FLAVONOIDS AS POTENTIAL CHEMOPREVENTIVE AGENTS (Javier Espinosa-Aguirre,
México)
12:35–12:50 IDENTIFICATION OF GENES REGULATED BY THE CO-FORMULATION OF INTERFERON-ALPHA
AND GAMMA CIGB28-A IN GLIOBLASTOMA CELL LINE U87MG BY ILLUMINA MICROARRAY ANALYSIS
(Dania Vázquez-Blomquist, Cuba)
12
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
12:55–13:10 GENETIC FACTORS FOR MULTIPLE SCLEROSIS AND NEUROMYELITIS OPTICA IN CUBAN
PATIENTS. (Dr. María Elena Fernández Cossio, CIGB, La Habana, Cuba)
SYMPOSIUM ON PHARMACOLOGY OF CYTOCHROME P450,
TRANSPORTERS AND OMICS (ROOM 3)
MONDAY 15 (15:00- 17:00)
Topics: Pharmacogenomic
Chairs: Lawrence J. Lesko (USA) / Javier Espinosa (México)
15:00–15:30 CIGB-522 MODULATES THE IMMUNE RESPONSE OF TUMOR CELL LINES (Julio Raúl
Fernández, Cuba)
15:30–15:50 GENE EXPRESSION REGULATION OF A SET OF GENES BY THE ANTITUMOR PEPTIDE CIGB300- IN AML CELL LINES (Dania Vázquez-Blomquist, Cuba)
15:50–16:10 DNA ANALYSIS OF MICROBES IN THE COLON OF RAT MODEL OF ULCERATIVE COLITIS
(Isabel Guillén, Cuba)
16:10–16:30 A WEBSITE TO PROMOTE CONTENTS AND RESOURCES ABOUT THE CLINICAL APPLICATIONS
OF THE OMICS TECHNOLOGIES (Orlando Serrano-Barrera, Cuba)
16:30–17:00 GENERAL DISCUSSION
WORKSHOP OF NEUROIMMUNOLOGY (ROOM 4)
MONDAY 15 (09:00-13:00)
Topics: Neuroimmune Interaction and repair of brain damage
Chairs: Carlos Alberto Goncalves (Brazil) / Alina González Q (Cuba)
09:00-09:25 NEUROPLASTICITY: PRESENT AND FUTURE (Jorge Bergado Rosado, CIREN, Cuba)
09:30-09:50 ASTROCYTE SIGNALING IN NEUROINFLAMMATION (Cinthia Farina, San Raffaele Scientific
Institute, Italy)
09:55-10:20 MARKERS OF ASTROGLIAL ACTIVITY IN ALZHEIMER´S DISEASE (Carlos Alberto Gonçalves,
UFRGS,Brazil)
10:25-10:45 IL-12/IL-23 SIGNALING AND GLIAL ACTIVATION IN ALZHEIMER’S DISEASE. (Ileana
Lopategui, ISCM-H, Cuba)
10:50-11:05 S100 BETA AND BDNF IN PATIENTS WITH LUPUS AND PSYCHIATRIC DISORDERS. (Elena
Noris Garcia, Nephrology Institute, Cuba)
11:10-11:25 Coffee break
13
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
11:25-11:50 NEUROBIOLOGICAL MECHANISMS IMPLICATED IN THE IMPAIRMENT INDUCED BY THE
PRO-INFLAMMATORY CYTOKINE IL-1Â ON FEAR MEMORY PROCESSES (Patricia Gonzalez, Faculty of
Chemical Science - UNC, Argentina)
11:55-12:15 NEUREGULIN 1 REGULATES EXCITABILITY OF FAST-SPIKING NEURONS THROUGH KV1.1
AND ACTS IN EPILEPSY (Xiao-Ming Li. Zhejiang, Zhejiang University China)
12:20-12:45 IMPACT OF PLANT DERIVED FLAVONOIDS ON GLIA MODULATION AND
NEURODEGENERATIVE DISEASES. (Silvia Lima Costa, Universidade Federal da Bahia, Brazil)
WORKSHOP OF NEUROIMMUNOLOGY (ROOM 4)
MONDAY 15 (15:00-18:00)
Topic: Modulating functions in neurological diseases
Chairs: Salvatore Cuzzocrea (Italy) / René Delgado (Cuba)
15:00-15:25 NEUROPROTECTION IS A PENDING TASK OF THE NEUROSCIENCES OF THE XXI CENTURY
(Julio Cesar García, Havana University, Cuba)
15:30-15:45 NEUROPROTECTION BY LONG-CHAIN FATTY ACIDS IN TRAUMA: THE CONTROL OF
NEUROINFLAMMATION (Salvatore Cuzzocrea, University of Messina, Italy)
15:50-16:10 FUMARIC ACID ESTERS ATTENUATE SECONDARY DEGENERATION AND PROMOTE
FUNCTIONAL RECOVERY FOLLOWING EXPERIMENTAL SPINAL CORD INJURY (Emanuela Esposito,
University of Messina, Italy)
16:15-16:30 INFLAMMATORY AND NEUROTROPHIC RESPONSE TO GLUTATHIONE DEPLETION IN THE
SUBSTANTIA NIGRA PARS COMPACT OF RATS. (Mei-Li Díaz Hung, CIREN, Cuba)
16:35-16:55 MITOCHONDRIA: A TARGET FOR NEUROPROTECTIVE INTERVENTIONS IN CEREBRAL
ISCHEMIA-REPERFUSION (Gilberto L Pardo- Andreu, CIDEM, Cuba)
17:00−
−17:20 ANTIPARKINSONIAN ANTIDYSKINETIC EFFECT OF PHYTODRUG MUCUNAPRURIENS IN RAT
MODEL OF PARKINSON DISEASE (Liliana Francis Turner, Ibague University, Colombia)
17:25-17:40 NEUROPROTECTIVE EFFECT OF JM-20, A NOVEL MULTI-TARGET LIGAND, IN DIFFERENT
EXPERIMENTAL MODELS RELATED TO CEREBRAL ISCHEMIA (Yanier Núñez, CIDEM, Cuba)
17:40-18:00 NEUROPHARMACOLOGICAL STUDIES OF NEW NEUROPROTECTIVES COMPOUNDS IN
CUBA. TODAY BASIC AND APPLIED SCIENCE: TOMORROW NEW DRUGS AGAINST CEREBROVASCULAR
DISORDERS AND NEURODEGENERATIVE DISEASES (Rene Delgado, CIDEM, Cuba)
14
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
WORKSHOP OF NEUROIMMUNOLOGY (ROOM 4)
TUESDAY 16 (9.00-13.40)
Topic: Molecular mechanisms in genetic and neurodevelopmental disorder
Chairs: Margaret Fahnestock (Canada) / Maria Robinson (Cuba)
09:00-9:25 MOLECULAR REGULATION OF STEM CELLS IN DOWN’S SYNDROME AND
NEURODEGENERATION (Michael Clarke, Stanford Institute, USA)
09:30-9:50 ANTINEURONAL ANTIBODIES AGAINST NEUROTRANSMITTER RECEPTORS AND SYNAPTIC
PROTEINS IN SCHIZOPHRENIA: CURRENT KNOWLEDGE AND CLINICAL IMPLICATION (Johann Steiner,
Magdeburg University, Germany)
09:55-10:20 GENE EXPRESSION CHANGES IN AUTISM: EVIDENCE FOR NEUROINFLAMMATION (Dario
Siniscalco, Second University of Naples,Italy)
10:25-10:50 DECREASED TRKB AND MTOR SIGNALING PATHWAYS IN HUMAN IDIOPATHIC AUTISM AND
IN A RODENT MODEL OF AUTISM (Margaret Fahnestock, Ontario University, Canada)
10:55-11:10 Coffee break
11:15-11:30 HLA ANTIGENS IN AUTISTIC CUBAN PATIENTS (Arturo Chang, CICEL, Cuba)
11:35-11:55 CYTOKINE PROFILE AND CLINICAL DATA IN AUTISM CUBAN PATIENTS (Maria Robinson,
CIREN, Cuba)
12:00-12:25 ELECTROPHYSIOLOGICAL EVENTS IN ASD CUBAN PATIENTS (Lilia Morales Chacón, CIREN,
Cuba)
12:30-13:00 TRANSCRANIAL MAGNETIC STIMULATION AND ADHD (Lázaro Gomez, CIREN, Cuba)
WORKSHOP OF NEUROIMMUNOLOGY (ROOM 4)
TUESDAY 16 (15:00-17:40)
Topic: First Symposia on Multiple Sclerosis and related disorders
Chairs: Harmut Wekerle (Germany)// Giselle Pentón (Cuba)
15:00-15:25 MULTIPLE SCLEROSIS AND THE GUT FLORA: A BACTERIAL BIOREACTOR FUELS BRAIN
AUTOIMMUNITY (Harmut Wekerle, Max Planck Institute, Germany)
15:30-15:55 MICROPARTICLES IN THE CEREBROSPINAL FLUID REFLECT MICROGLIA/MACROPHAGE
ACTIVATION IN RODENT AND HUMAN NEUROLOGICAL DISORDER (Roberto Furlan, San Raffaele
Scientific Institute, Italy)
16:00-16:25 NEUROINFLAMMATION AND NEURODEGENERATION: INDEPENDENT
NEUROPATHOLOGICAL TARGETS OF EAE? (J Carvalho Tavares, Minas de Gerais University, Brazil)
15
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
16:30−
−16:45 IFN-B AND C-PHYCOCYANIN COMBINATION IN VITRO IMMUNOMODULATORY RESPONSES
(Majel Cervantes, CIGB, Cuba)
− 17:15 THALAMIC ATROPHY CORRELATES WITH COGNITIVE DYSFUNCTION IN RELAPSING16:50−
REMITTING MULTIPLE SCLEROSIS PATIENTS TREATED WITH NATALIZUMAB (Jacqueline Bernard. Chicago
University, USA)
17:20-17:45 MULTIPLE SCLEROSIS: GREATER EXPECTATIONS ON NOVEL COMBINED THERAPY (Giselle
Pentón, CIGB, Cuba)
SATELLITE MEETING: PROTEIN KINASES AS DRUGGABLE
PHARMACOLOGICAL TARGET. FOCUS ON PROTEIN KINASE CK2 (ROOM 5)
MONDAY 15 (09:00-13:25)
Chairs: Olaf-Georg Issinger (Denmark)/Silvio E Perea (Cuba)
09:00-09:10 OPENING REMARKS: TOWARDS VALIDATION OF CK2 AS A CLINICAL CANCER TARGET?
(Silvio E Perea, Dept of Cancer, Center for Genetic Engineering and Biotechnology, Havana, Cuba)
09:15-09:40 CIGB-300 IMPAIRS THE CK2 BETA-DEPENDENT PHOSPHORYLATION (Teresa Núñez, Dept
of Systems Biology, Center for Genetic Engineering and Biotechnology, Havana, Cuba)
09:45-10:10 SMALL COMPOUND INHIBITORS OF PROTEIN KINASE CK2: STUDIES IN TUMOR CELLS AND
CARDIOMYOCYTES (Olaf-Georg Issinger, Dept Biochem & Mol Biology, Univ Southern Denmark, Odense,
Denmark)
10:15-10:40 PROTEIN KINASE CK2: LESSONS FROM KNOCKOUT MICE (Brigitte Boldyreff, KinaseDetect
ApS, R&D, Odense, Denmark)
10:45-11:10 CK2: INTERSECTIONS WITHIN THE REGULATORY POST-TRANSLATIONAL MODIFICATION
NETWORKS (David Litchfield, Dept of Biochem, Univ of Western Ontario, London Ontario, Canada)
11:15-11:30 COFFEE BREAK
Chairs: David Litchfield (Canada)/ Isabel Domínguez (USA)
11:30-11:55 ABROGATION OF CASEIN KINASE 2 (CK2)-MEDIATED SIGNALING USING A PEPTIDE
INHIBITOR IMPAIRS VIABILITY AND PROLIFERATION OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA CELLS
(Yasser Perera, Center for Genetic Engineering and Biotechnology, Havana, Cuba)
12:00-12:25 MINING CK2 IN CANCER (Isabel Dominguez, Boston University School of Medicine, Boston,
MA, USA)
12:30-12:55 THE MAPK SIGNALING PATHWAY PMK1P AND MAINTENANCE OF CELL INTEGRITY IN
SCHIZOSACCHAROMYCES POMBE (Sandra Cruz, Universidad Nacional de Chimborazo, Ecuador)
16
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
13:00-13:25 INHIBITION OF PROTEIN TYROSINE PHOSPHATASE 1B (PTP1B) OF CUBAN PLANTS EXTRACTS
AS PROMISING TYPE 2 ANTI-DIABETES AGENTS (Eva Marrero, Dept of Biopharmaceutical Development,
CENSA, Havana, Cuba)
SYMPOSIUM OF ATHEROSCLEROSIS (ROOM 5)
TUESDAY 16 (9.00-13.00)
Chairs: Proctor Spencer (Canada)/Ana María Vázquez (Cuba)
09:00-09:30 THE EFFECTS OF TOBACCO ON THE DEVELOPMENT OF ATHEROSCLEROTIC LESIONS. AN
AUTOPSY-BASED STUDY (Emilio Fernández-Britto, Center for Research and References of Atherosclerosis
of Havana (CIRAH), University of Medical Science of Havana, Cuba)
09:35-10:05 CONTRIBUTIONS OF INTESTINAL APOB LIPOPROTEINS TO PLAQUE CHOLESTEROL:
EVIDENCE FROM BENCH TO BEDSIDE DURING CHILDHOOD OBESITY (Proctor Spencer, Metabolic and
Cardiovascular Disease Laboratory, Alberta Diabetes and Mazankowski Heart Institutes, University of
Alberta, Canada)
10:10-10:40 NON-ALCOHOLIC FATTY LIVER DISEASE, FRAMINGHAM RISK SCORE AND FLOW-MEDIATED
DILATION IN PATIENTS WITH CARDIO-METABOLIC RISK FACTORS (Francesco Angelico, Departments of
Internal Medicine and Medical Specialties and Department of Public Health and Infectious Diseases,
Sapienza University, Rome, Italy)
10:45-11:15 COMBINED SUB-OPTIMAL DOSES OF ROSUVASTATIN AND BEXAROTENE IMPAIRS
ANGIOTENSIN II-INDUCED ARTERIAL MONONUCLEAR CELL ADHESION AND ATHEROSCLEROSIS LESION
FORMATION (María Jesús Sanz, Department of Pharmacology, Faculty of Medicine, University of
Valencia. Institute of Health Research INCLIVA, University Clinic Hospital of Valencia, Spain)
11.15-11.30 COFFEE BREAK
11.30-12.00 VISFATIN/NAMPT, VASCULAR INFLAMMATION AND ENDOTHELIAL SENESCENCE: A ROLE
IN ATHEROSCLEROSIS? (Concha Peiro, Department of Pharmacology, School of Medicine, Universidad
Autónoma de Madrid, Madrid, Spain)
12.05-12.35 ANTI-ATHEROSCLEROTIC EFFECT OF ACTIVE IMMUNIZATION WITH AN ANTIPROTEOGLYCAN ANTIBODY IN THERAPEUTIC SETTINGS. (Ana María Vázquez, Center of Molecular
Immunology, Havana, Cuba)
12.40-12:55 GENERAL DISCUSSION
17
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
SYMPOSIUM OF ATHEROSCLEROSIS SYMPOSIUM (ROOM 5)
WEDNESDAY 17 (09:00-13:00)
Chairs: Francesco Violi (Italy)/Livan Delgado-Roche (Cuba)
09:00-09:30 NADPH OXIDASE AND CARDIOVASCULAR DISEASES (Francesco Violi, Sapienza University,
I Clinica Medica, Rome, Italy)
09:35-10:05 OXIDATIVE STRESS AND PLATELET ACTIVATION IN OBESITY (Giovanni Daví, «G. d’ Annunzio»
University Foundation, Center of Excellence on Aging, University of Chieti, Italy)
10:10-10:40 DIAGNOSTIC AND THERAPEUTIC POTENTIAL OF STAT1 AND IRF8 IN CARDIOVASCULAR
DISEASE (Hans Bluyssen, Department of Human Molecular Genetics, Institute of Molecular Biology
and Biotechnology, Faculty of Biology, Adam Mickiewicz University, Poznan Poland)
10:45-11:15 EFFECTS OF OBEX® IN OVERWEIGHT AND OBESE SUBJECTS WITH IMPAIRED FASTING
GLUCOSE: A PILOT STUDY (Eduardo Cabrera, National Institute of Endocrinology, Havana, Cuba)
11:15-11:30 COFFEE BREAK
11:30-12:00 HYPOCHOLESTEROLEMIC AND ANTI-ATHEROSCLEROTIC EFFECTS OF CRUDE LEAF EXTRACT
OF MORINGA OLEIFERA IN APOE KO MICE (Dasha Fuentes, National Center for Laboratory Animal
Breeding, Mayabeque, Cuba)
12:05-12:35 REDOX REGULATION AND ANTI-INFLAMMATORY EFFECTS OF AN ANTI-PROTEOGLYCAN
ANTIBODY IN ANIMAL MODELS OF ATHEROSCLEROSIS. (Livan Delgado-Roche, Center of Marine
Bioproducts, Havana, Cuba)
12:40-12:55 GENERAL DISCUSSION
SYMPOSIUM OF PAIN AND INFLAMMATION (ROOM 6)
MONDAY 15 (09:00-13:00)
Topic: Inflammation and Pain
Chairs: Marcelo Kreiner (Uruguay)/Beatriz Garrido (Cuba)
09:00-09:30 TARGETING NEUROINFLAMMATION WITH NOVEL SYNTHETIC AND NATURAL
NEUROPROTECTIVE COMPOUNDS. A NEW APPROACH TO DEVELOPMENT THERAPIES FOR
NEUROPATHIC PAIN (Beatriz Garrido, Laboratory of Pharmacology and Toxicology, Center of Research
and Drug Development, Havana, Cuba)
09:35-10:05 ANTINOCICEPTION PRODUCED BY THALASSIA TESTUDINUM EXTRACT BM-21 IS MEDIATED
BY THE INHIBITION OF ACID SENSING IONIC CHANNELS (ASIC) BY THE PHENOLIC COMPOUND
THALASSIOLIN B (Roberto Menéndez, Department of Pharmacology, Center of Marine Bioproducts,
Havana, Cuba)
18
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
10:10-10:40 EFFECTS OF PALMITOYLETHANOLAMIDE AND SILYMARIN COMBINATION THERAPY IN AN
ANIMAL MODEL OF KIDNEY ISCHEMIA AND REPERFUSION (Irene Paterniti, Department of Biological
and Environmental Sciences, University of Messina, Italy)
10:45-11:15 ANTI-INFLAMMATORY AND ANTI-HYPERNOCICEPTIVE EFFECTS OF C-PHYCOCYANIN ON
MBSA-INDUCED ARTHRITIS IN MICE (Javier Marín, Center for Research and Biological Evaluations,
Institute of Pharmacy and Food, University of Havana, Cuba)
11:15-11:30 COFFEE BREAK
Chairs: Marcelo Kreiner (Uruguay)/Beatriz Garrido (Cuba)
11:35-12:05 IMPACT OF CHRONIC SOCIAL STRESS ON THE IMMUNE MECHANISMS OF PROINFLAMMATORY SIGNALING ACTIVATION IN THE SMALL INTESTINE OF RATS (Inna Topol, Department
of Microbiology, Virology and Immunology Zaporozhye State Medical University, Zaporozhye, Ukraine)
12:10-12:40 CLINICAL AND NEUROPHYSIOLOGICAL CONSIDERATIONS IN FACIAL PAIN WITH EMPHASIS
IN VISCERAL REFERRED PAIN AND TRIGEMINAL NEURALGIA (Marcelo Kreiner, Department of General
and Oral Physiology, University of Republic, Uruguay)
SYMPOSIUM OF HEREDITARY ATAXIAS (ROOM 7)
TUESDAY 16 (09:00-13:00)
Chairs: Georg Auburger (Germany) / Luis Velázquez (Cuba)
09:00-9:30 MOLECULES BEHIND SCA2 (Georg Auburger, Universidad de Frankfurt, Frankfurt,
Germany)
9:30-10:00 PRODROMAL BIOMARKERS FOR SPINOCEREBELLAR ATAXIA TYPE 2 (Luis Velázquez, CIRAH,
Holguín, Cuba)
10:00-10:30 EXPANDING THE ROLE OF RNA-BINDING PROTEINS IN NEURODEGENERATIVE DISEASE:
TDP-43, ATAXIN 2, C9ORF72 AND BEYOND (Aaron Gitler, Stanford University School of Medicine,
Stanford, USA)
10:30-11:00 BIOMARKERS IN SCAS (Christopher Gómez, University of Chicago School of Medicine,
Chicago, USA)
11:00-11:30 SPINOCEREBELLAR ATAXIA TYPE 2: PROGRESSION OF SACCADIC EYE MOVEMENT
ABNORMALITIES OVER 5 YEARS (Roberto Rodríguez, CIRAH, Holguín, Cuba)
11:30-11:45 COFFEE BREAK
11:45-12:15 ELECTROPHYSIOLOGICAL FEATURES OF SPINOCEREBELLAR ATAXIA TYPE 7 (Rigoberto
González, Instituto Nacional de Rehabilitación, México DF, México)
12:15-12:45 CLINICAL AND GENETIC CHARACTERIZATION OF SPINOCEREBELLAR ATAXIA TYPE 7 IN
MEXICAN POPULATION (Cesar Ceredo-Zapata, Centro de Rehabilitación Veracruz, México)
19
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
12:45-13:15 ELECTRONEUROGRAPHIC ALTERATIONS OF TRIGEMINAL AND FACIAL NERVES IN SCA2:
FACIAL MORPHOLOGY RELATION (Jacqueline Medrano, CIRAH, Holguín, Cuba)
13:15-13:45 SCA2 PREDICTIVE TESTING IN CUBA: CHALLENGING CONCEPTS AND PROTOCOL
EVOLUTION (Yaimeé Vázquez, CIRAH, Holguín, Cuba)
13:45-14:30 LUNCH
14:30-14:50 NEUROREHABILITATIVE THERAPY IN SPINOCEREBELLAR ATAXIA TYPE 2: EXPERIENCES
FROM THE CUBAN PROGRAM. (Julio Cesar Rodríguez, CIRAH, Holguín, Cuba)
14:50-15:10 AUDITORY VERBAL MEMORY AND LEARNING CURVES IN PATIENTS WITH
SPINOCEREBELLAR ATAXIA TYPE 7 (Michelle Rodríguez-Trejo, Universidad de las Américas, México
DF, México)
15:10-15:30 NEUROPROTECTIVE EFFECT OF MAGNETIC FIELDS IN BIOMODELS OF ATAXIA SCA2
(Consuelo Gonzalez, CENPALAB, Artemisa, Cuba)
15:30-15:50 PROCESO PSICOLÓGICO Y AFRONTAMIENTO EN EL NÚCLEO FAMILIAR PRIMARIO Y
PACIENTE CON ATAXIA HEREDITARIA (Víctor Manuel González, Centro de Rehabilitación Integral,
Zimapán, Mexico) .
15:50-16:10 HIGHER SUPEROXIDE DISMUTASE AND CATALASE ACTIVITIES ARE ASSOCIATED WITH A
LESS SEVERE CLINIC EXPRESSION OF SPINOCEREBELLAR ATAXIA TYPE 2. (Dennis Almaguer, CIRAH,
Holguín Cuba).
16:10-16:30 REHABILITACION COGNITVA: UNA PROPUESTA EN LA ENFERMEDAD VASCULAR
CEREBRAL. (Daniel Alfredo Landínez, Instituto Nacional de Rehabilitación, México DF).
16:30-16:50 EFECTO DE LA INTERVENCIÓN SENSORIOMOTRIZ EN LOS NIVELES DE NORADRENALINA
HIPOCAMPALES Y PONTINOS Y EN LA MORFOLOGÍA SINÁPTICA EN RATAS ADULTAS CON ABLACIÓN
CORTICAL. (Laura E. Ramos, Instituto Nacional de Neurología y Neurocirugía, México DF, México).
16:50-17:10 CUBAN FAMILIES WITH SPINOCEREBELLAR ATAXIA TYPE 7. (Yanetza González Zaldívar,
CIRAH, Holguín, Cuba).
COMMERCIAL PRESENTATION SESSION (Room 5)
WEDNESDAY 17 (15:00-17:00)
15:00-15:20 MEDIA, SERA AND AUXILIARY PRODUCTS FOR CELL CULTURE AND MOLECULAR
BIOLOGY. Hofmann, M. Seafront Biotech GmbH Logistics & Management, Franz-Jacob-Str. 4A,
10369 Berlin, featuring Biological Industries Israel Beit Haemek Ltd., Beit Haemek, Israel
15:30-15:50 HIGH-PERFORMANCE PRECISION ANALYTICAL SYSTEMS. Hofmann, M. Seafront Biotech
GmbH Logistics & Management, Franz-Jacob-Str. 4A, 10369 Berlin, featuring Analytik Jena AG,
Analytical Instrumentation, Konrad-Zuse-Straße 1, 07745 Jena Germany
20
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
16:00-16:20 SPECIALIZING IN CHO|360-HCP ELISA. Hofmann, M. Seafront Biotech GmbH Logistics &
Management, Franz-Jacob-Str. 4A, 10369 Berlin, featuring BioGenes GmbH, Köpenicker Straße 325,
D-12555 Berlin, Germany
VACCINE PLENARY SESSION (Room 2)
MONDAY 15 (09:00-13:00)
Chairs: Dr. Sonia Pagliusi (WHO) / Dr. Rolando Ochoa (Cuba)
09:00-09:05 OPENING SESSION
09:05-09:45 THE EXPANDED IMMUNIZATION PROGRAM IN AMERICA (Nancy Vasconez, PAHO-WHO,
Nicaragua)
09:35-10:05 VACCINATION STRATEGIES: THE CUBAN EXPERIENCE (Rolando Ochoa, Finlay Institute Cuba)
10:05-10:35 DCVMN INTERNATIONAL UPDATES (Sonia Pagliusi, DCVMN-WHO, Brazil)
10:35-11:05 SURROGATES OF PROTECTION, PAST, PRESENT AND FUTURE (Jamie Findlow, Public Health
England, UK)
11:05-11:35 MONOCLONAL ANTIBODIES: AN ANALYTICAL TOOL IN VACCINE DEVELOPMENT (Elizabeth
González, Finlay Institute. Cuba)
11:35-12:05 RETHINKING TECHNOLOGY TRANSFER FOR A FASTER ACCESS TO INNOVATIVE VACCINES
(Aldo Tagliabue, Siena, Italy)
12:05-12:35 ETHICAL ISSUES AND VACCINES (Glenn Ellis, Strategies for Well-Being, Philadelphia, USA)
12:35-13:00 DISCUSSION
SYMPOSIUM MENINGOCOCCAL VACCINES (Room 2)
MONDAY 15 (15.00-18.00)
Chairs: Dr Ray Borrow (UK) / Dr. Reinaldo Acevedo (Cuba)
15:00-15:05 OPENING SESSION
15:05-15:30 EVOLVING STRATEGIES FOR MENINGOCOCCAL CONJUGATE VACCINATION (Ray Borrow,
Vaccine Evaluation Unit, Public Health England, PHE. UK)
15:30-15:55 A NEW THERMOSTABLE PENTAVALENT (A/C/Y/W/X) MENINGOCOCCAL CONJUGATE
VACCINE FOR AFRICA (Marc LaForce, Serum Institute of India and PATH, Seattle. USA)
15:55-16:20 NOVEL MENINGOCOCCAL VACCINES: QUANTITATIVE APPROACHES FOR EFFECTIVENESS
PREDICTION AND POST-IMPLEMENTATION SURVEILLANCE (Duccio Medini, GSK. Italy)
21
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
16:20-16:45 UNVEILING THE TRUE COMPLEXITY OF THE MENINGOCOCCAL ST-11 COMPLEX (Jay
Lucidarme, Vaccine Evaluation Unit, Public Health England, PHE. UK)
16:45-17:05 OBTAINING AND APPLICABILITY OF MONOCLONAL ANTIBODIES TO CAPSULAR
POLYSACCHARIDE SEROGROUPS A, C, W, Y AND X OF NEISSERIA MENINGITIDIS (Fidel Ramirez, Finlay
Institute. Cuba)
17:05-17:25 ANALYTICAL TRANSFERENCE PROCESS OF AN ELISA FOR DETERMINING CONTENT OF
POLYSACCHARIDES A,C,Y,W IN MULTIVALENT VACCINES (Mario Landys Chovel, Finlay Institute. Cuba)
17:25-17:35 DISCUSSION
17:35-17:55 UNIQUE ASPECTS OF MENINGOCOCCAL PORB IMMUNE STIMULATION AND USE AS A
VACCINE ADJUVANTE (Lee Wetzler, Boston University School of Medicine. USA)
17:55-18:15 AFPL1®: A NEW VACCINE ADJUVANT BASED ON NEISSERIAL MENINGITIDES OMV (Julio
Balboa, Finlay Institute. Cuba)
18:15-18:25 DISCUSSION
SYMPOSIUM MENINGOCOCCAL VACCINES (Room 2)
TUESDAY 16 (09.00-13.30)
Chairs: Dr Johan Holst (Norway) / Dr. Luis García (Cuba)
09:00-09:10 OPENING SESSION
09:10-09:35 LEARNING-POINTS FROM THE DEVELOPMENT OF PROTEIN-BASED MENB VACCINES
WITH BROAD STRAIN COVERAGE (Johan Holst, Norwegian Institute of Public Health NIPH. Norway)
09:35-10:00 FACTOR H-BINDING PROTEIN DISTRIBUTION AMONG CULTURE AND NON CULTURE
MENINGOCOCCI IN ENGLAND AND WALES: 2011-2013 (Stephen Clark, Vaccine Evaluation Unit,
Public Health England, PHE. UK)
10:00-10:25 GLOBAL EXPRESSION PROFILING OF NEISSERIA MENINGITIDIS FACTOR H BINDING
PROTEIN (FHBP) BY AN ANTIBODY-INDEPENDENT MASS SPECTROMETRY BASED METHODOLOGY
(Marcia Giuliani, Novartis. Italy)
10:25-10:45 POOLED HSBA TITRES PREDICT SERORESPONSE RATES OF INFANTS AND TODDLERS
VACCINATED WITH 4CMENB (Sonia Budroni, GSK. Italy)
10:45-11:05 UPDATE OF THE SAFETY PROFILE OF MENINGOCOCCAL B&C VACCINE VA MENGOC BC
(Ivan Cuevas, Finlay Institute. Cuba)
11:05-11:20 EFFECT OF THE ECULIZUMAB (SOLIRIS®), ON THE MENINGOCOCCAL SEROGROUP B
(MENB) SERUM BACTERICIDAL ANTIBODY (SBA) ASSAY (Xillian Bai, Public Health England, PHE.UK)
11:20-11:35 DISCUSSION
22
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
11:35-12:00 OVERVIEW OF THE PROJECT-AW OMV VACCINE-FROM MICE TO MEN (Einar Rosenqvist,
Norwegian Institute of Public Health NIPH. Norway)
12:00-12:25 PHASE I CLINICAL STUDY-DESIGN AND SAFETY OF AW OMV CANDIDATE (Luis Garcia,
Finlay Institute. Cuba)
12:25-12:50 IMMUNE RESPONSES IN HUMANS AFTER VACCINATION WITH A NOVEL OUTER
MEMBRANE VESICLE VACCINE AGAINST SEROGROUP A AND W MENINGOCOCCAL DISEASE (Lisbeth
Naess, Norwegian Institute of Public Health NIPH. Norway)
12:50-13:10 NEW VACCINE STRATEGIES AGAINST NESISSERIA MENINGITIDIS SEROGROUP X
(Reinaldo Acevedo, Finlay Institute. Cuba)
13:10-13:25 DISCUSSION
SYMPOSIUM ENTERIC VACCINE (Room 2)
TUESDAY 16 (15.00-18.00)
Chairs: Imran Khan (USA) / Thomas Wierzba (USA)
15:00-15:05 OPENING SESSION
15:05-15:25 GLOBAL BURDEN OF TYPHOID AND PARATYPHOID AND STRATEGIES FOR ITS CONTROL
(Sushant Sahastrabuddhe, International Vaccine Institute. Republic of Korea)
15:25-15:45 TYPHOID VACCINE DEVELOPMENT AND THE POTENTIAL FOR CONTROL OF ENTERIC
FEVER (Imran Khan, Coalition against Typhoid Sabin Institute. USA)
15:45-16:05 DEVELOPMENT OF VI CONJUGATE VACCINE AGAINST TYPHOID (Sonsire Fernández,
Finlay Institute. Cuba)
16:05-16:20 DISCUSSION
16:20-16:40 ENTERIC DISEASE VACCINE DEVELOPMENT FOR CHILDREN LESS THAN 2 YEARS OF AGE
(Khalid Ali Syed, International Vaccine Institute. Republic of Korea)
16:40-17:00 ETEC VACCINES (Thomas Wierzba, Enteric Vaccine Initiative PATH. USA)
17:00-17:20 CLINICAL PROOF-OF-CONCEPT OF SBVGH SHIGELLA SONNEI GENERAL MODULES FOR
MEMBRANE ANTIGENS (GMMA) VACCINE ADMINISTERED BY INTRAMUSCULAR ROUTE (Audino
Podda, SBVGH, Sienna, Italy)
17:20-17:40 PRELIMINARY SAFETY PROFILE OF THE CHOLERA 638 VACCINE CANDIDATE (Rodrigo
Valera, Finlay Institute. Cuba)
17:40-17:55 DISCUSSION
23
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
SYMPOSIUM PNEUMOCOCCAL VACCINES (Room 2)
WEDNESDAY 17 (09:00-13:00)
Chairs: David Goldblatt (UK) / Vicente Vérez (Cuba)
09:00-09:15 OPENING SESSION
09:15-09:45 GLOBAL IMPACT OF PCV‘S AND LESSON LEARNED/ EPIDEMIOLOGY OF PNEUMOCOCCAL
SEROTYPES IN 2015, IMPLICATIONS FOR NEW CONJUGATE VACCINES (Katherine O‘Brien, Center for
American Indian Health/International Vaccine Access Center. USA)
09:45-10:15 PCVS-FROM IMMUNOGENICITY THROUGH CARRIAGE TO PUBLIC HEALTH IMPACT (Ron
Dagan, Soroka University Medical Center. Israel)
10:15-10:45 CHANGES IN PNEUMOCOCCAL DISEASE IN THE VACCINE ERA/PNEUMOCOCCAL
EXPERIENCES IN LATIN AMERICA UNIVERSAL VACCINATION (María Catalina Pírez, Centro
Hospitalario Pereira Rosell. Uruguay)
10:45-11:15 NEXT GENERATION PNEUMOCOCCAL VACCINES, CHALLENGES INCLUDING
EFFECTIVENESS (David Goldblatt, Institute of Child Health of University College London/WHO
Reference Laboratory for Pneumococcal Serology. UK)
11:15-11:45 SURVEILLANCE/IMPACT ASSESSMENT OF PCV INTRODUCTION IN GAVI COUNTRIES:
OPPORTUNITIES FOR LOWERING COST BY INTRODUCING NEW VACCINES AND/OR REDUCED
SCHEDULES. (Gail Rodgers, The Bill and Melinda Gates Foundation. USA)
11:45-12:00 DISCUSSION
12:00-12:30 CHANGES IN PNEUMOCOCCAL DISEASE IN THE VACCINE ERA/PNEUMOCOCCAL
EXPERIENCES IN LATIN AMERICA UNIVERSAL VACCINATION (Maria Catalina Pírez, Centro
Hospitalario Pereira Rosell. Uruguay)
12:30-13:00 CUBAN PNEUMOCOCCAL CONJUGATE VACCINE: A NEW MORE COST-EFFECTIVE PCV7
IN PCV13 ERA (Vicente Vérez, Finlay Institute. Cuba)
13:00-13:30 STRATEGY FOR CLINICAL AND IMPACT EVALUATION OF A NEW CUBAN
PNEUMOCOCCAL CONJUGATE VACCINE (Nivaldo Linares, Finlay Institute. Cuba)
SYMPOSIUM VIRAL VACCINES (Room 2)
THURSDAY 18 (09:00-13:00)
Topic: Viral Vaccines
Chairs: María Guadalupe Guzmán (IPK, Cuba) / Laureano Mestra (Colombia)
09:00-09:05 OPENING SESSION
09:05-09:35 VIRUS-LIKE PARTICLES AND NUCLEOPARTICLES AS VACCINE CANDIDATES (Gerardo Guillén,
CIGB. Cuba)
24
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
09:35-10:05 DENGUE VACCINE, ADVANCES AND CHALLENGES (María Guadalupe Guzmán, IPK. Cuba)
10:05-10:25 EVALUATION OF THE IMMUNOGENICITY AND PROTECTIVE EFFICACY OF A TETRAVALENT
SUBUNIT VACCINE CANDIDATE AGAINST DENGUE VIRUS (Laura Lazo, CIGB Cuba)
10:25-10:45 RECOMBINANT DENGUE 2 VIRUS NS3 PROTEIN CONSERVES STRUCTURAL ANTIGENIC AND
IMMUNOLOGICAL PROPERTIES RELEVANT FOR DENGUE VACCINE DESIGN (Rosa Ramirez, IPK. CUBA)
10:45-11:05 HBV AND HCV MUTANTS ASSOCIATE WITH VACCINE ESCAPE AND ANTIVIRAL RESISTANCE
(Licel Rodríguez, IPK. CUBA)
11:05-11:25 MOLECULAR EPIDEMIOLOGY OF HPV IN WOMAN FROM COAST REGION OF ECUADOR
(Cesar Bedoya, INSPI. ECUADOR)
11:25-11:45 MOLECULAR EPIDEMIOLOGY OF HPV IN CUBAN POPULATION (Celia María Limia, IPK.
CUBA)
11:45-12:05 MEASLES, RUBELLA AND MUMPS ANTIBODIES DETECTION AFTER PRIMARY MMR
VACCINATION IN CHILDREN BETWEEN 14 TO 17 YEARS OLD (María de los Angeles Ribas, IPK. CUBA)
12:05-12:25 ETHIC CONSIDERATIONS IN VACCINE DEVELOPMENT (Laureano Mestra, PAHO. COLOMBIA)
12:25-12:55 DISCUSSION
WORKSHOP THERAPEUTIC VACCINE (infectious disease) Room 3
TUESDAY 16 (09.00-13.30)
Topic1: Human Papillomavirus
Chairs: Dr. Rosella Franconi (Italy) / Dr. Isis Torrens (Cuba)
09.00-09.05 OPENING SESSION
09.05-09.30 DEVELOPMENTS ABOUT PLANT-BASED VACCINES FOR THE IMMUNOTHERAPY OF
HUMAN PAPILLOMAVIRUS-RELATED CANCERS (Dr. Rosella Franconi, Italian National Agency for New
Technologies, ENEA. Italy)
09.35-10.00 A NOVEL STRATEGY TO IMPROVING ANTIGEN PRESENTATION FOR ACTIVE
IMMUNOTHERAPY IN HUMAN PAPILLOMAVIRUS RELATED CANCER BY LINKING OF THE HPV TYPE 16
E7 ANTIGEN TO A CELL PENETRATING PEPTIDE (Isis Torrens, Center for Genetic Engineering and
Biotechnology. Cuba)
10.05-10.30 NEW IMMUNOTHERAPIES AND NEW ORTHOTOPIC MOUSE MODELS (Dr. Aldo Venuti,
Laboratory of Virology HPV-UNIT, National Cancer Institute, Rome. Italy)
25
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
Topic 2: Hepatitis B Therapeutic vaccine
Chairs: Dr. Marie-Louise Michel (France) and Dr. Eduardo Pentón (Cuba)
10.35-10.40 OPENING SESSION
10.40-11.05 THERAPEUTIC VACCINES IN TREATING CHRONIC HEPATITIS B: FROM BENCH TO BEDSIDE
AND BACK (Dr. Marie-Louise Michel, Institute Pasteur. France)
11.10-11.30 IN VITRO STIMULATION WITH HBV THERAPEUTIC VACCINE CANDIDATE NASVAC ACTIVATES
B AND T CELLS FROM CHRONIC HEPATITIS B PATIENTS AND HEALTHY DONORS (Dr. Yadira Lobaina,
CIGB. Cuba)
11.35-12.00 NASVAC, A CUBAN HEPATITIS B THERAPEUTIC VACCINE CANDIDATE: PRINCIPLES, UPDATE
OF COMPLETED CLINICAL TRIALS (CT) AND ONGOING AND PLANNED CTS IN SEVERAL COUNTRIES (Dr.
Eduardo Pentón, CIGB. Cuba)
Topic 3: Adjuvants
12.05-12.10 OPENING NEW SESSION
12.10-12.35 ANTIVIRAL AND ADJUVANT PROPERTIES OF RIG-I AGONISTS (John Hiscott, Vaccine &
Gene Therapy Institute of Florida. USA)
12.40-13.05 INFLUENCE OF THE HAPTEN AND THE CONJUGATE DOSE ON THE CARRIER-INDUCED
HAPTEN-SPECIFIC SUPPRESSION ELICITED BY P64K IN MICE (Dr. Sonia Gonzalez, CIGB. Cuba)
SYMPOSIUM COMBINED VACCINE (Room 3)
TUESDAY 16 (15:00-18:00)
Topic: Inactivated Polio Vaccine
Chairs: Sonia Resik (IPK, Cuba) / Javier Martin (NIBSC, UK)
15.00-15.05 OPENING SESSION (Sonia Resik, Cuba)
15.05-15.35 THE ROLE OF INACTIVATED POLIO VACCINES IN THE POST-ERADICATION ERA (Javier
Martin, NIBSC. UK)
15.35-16.05 ASSESSMENT ON POLIO VACCINES NEEDED TO ASSURE ERADICATION (Robyn Iqbal,
BMGF. USA)
16.05-16.35 CUBAN CONTRIBUTIONS TO THE POLIO GLOBAL ERADICATION PROGRAM (Sonia Resik,
IPK, Cuba)
16.35-16.55 SABIN-IPV PROCESS DEVELOPMENT AND PRODUCTION PROCESS (Wilfried Bakker,
INTRAVAC. The Netherlands)
16.55-17.20 SAFETY AND IMMUNOGENICITY OF INACTIVATED POLIOVIRUS VACCINE BASED ON
SABIN STRAINS, WITH AND WITHOUT ALUMINUM HYDROXIDE (Yenisleidys Martínez, IPK. Cuba)
26
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
17.20-17.45 SABIN-IPV DEVELOPMENT TO SUPPORT POLIO ERADICATION GOALS: CLINICAL TRIALS
AND TECHNOLOGY TRANSFER (Wilfried Bakker, INTRAVAC. The Netherlands)
17.45-18.00 DISCUSSION
WORKSHOP REGULATORY SYSTEM (Room3)
WEDNESDAY 17 (09.00-17.30)
Topic: Biologic/Biotech Products
Chairs: Bradley Scott (Canada) and Yanet Hechavarría Núñez (Cuba)
09.00-09.05 OPENING SESSION (Yanet Hechavarría, Cuba)
09.05-09.30 SUBSEQUENT ENTRY BIOLOGICS (BIOSIMILARS) IN CANADA: A REVIEW OF KEY
REGULATORY ISSUES AND LESSONS LEARNT (Bradley Scott, Health Canada. Canada)
09.30-09.55 CHARACTERIZATION REGULATIONS TO MAKE POSSIBLE AN ABBREVIATED MECHANISM
OF APPROVAL OF CLINICAL TRIALS AND MARKETING OF PHARMACEUTICALS PRODUCTS FOR CANCER
INDICATION (Violeta Pérez, CECMED. Cuba)
09.55-10.15 GUIDELINES FOR BIOLOGICS/BIOSIMILARS PRODUCTS IN BRAZIL (Caroline Blades,
ANVISA. Brazil)
10.15-10.35 DEVELOPMENT AND EVALUATION OF BIOSIMILARS (Gilberto Castañeda-Hernández, Roche.
México)
10.35-11.00 BIOSIMILAR CLINICAL DEVELOPMENT: PATIENT ACCESSIBILITY AND AFFORDABILITY OF
LIFE-SAVING MEDICINES (Camilo Rodríguez, CENTER OF MOLECULAR IMMUNOLOGY, CUBA. Cuba)
11.00-11.25 EVALUATION OF REGULATORY CONVERGENCE FOR SIMILAR BIOLOGICAL MEDICINAL
PRODUCTS IN LATIN AMERICA (Celeste Sanchez, CECMED. Cuba)
11.25-11.45 DISCUSSION
11.45-12.00 REGULATORY DOCUMENTS FOR CELL THERAPY AND TISSUE ENGINEERING PRODUCTS
(Diana Patricia Hermida Vitar, CECMED. Cuba)
12.00-12.15 SURVEILLANCE AND TRACEABILITY OF CELLS AND TISSUES FOR CELL THERAPY (Lara
Alonso, ANVISA. Brazil)
12.15-12.30 CELL THERAPY IN CUBA: INTRODUCTION, DEVELOPMENT AND PERSPECTIVES (José A
Galván, IHI. Cuba)
Chairs: Gilberto Castañeda-Hernández (México) and Biorkys Yáñez (Cuba)
15.00-15.15 CURRENT APPROACH ON POST-APPROVAL CHANGES AND PROCESS CHANGES DURING
CLINICAL PHASE: INDUSTRY PERSPECTIVES (Gilberto Castañeda-Hernández, Mexico)
27
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
15.15-15.30 IMPACT OF THE NATIONAL INSPECTION PROGRAM ON QUALITY IMPROVEMENT OF
CLINICAL TRIALS (2001-2015) (Judith Cartaya, CECMED. Cuba)
15.30-15.45 THE QUALITY RISK MANAGEMENT APPROACH INTO THE REGULATORY INSPECTIONS
PROCESS (Biorkys Yáñez, CECMED. Cuba)
15.45-16.00 QUALITY RISK MANAGEMENT REGULATORY STANDPOINT AND IMPLEMENTATION (Yanelis
Martínez, CECMED. Cuba)
16.00-16.15 MANAGEMENT OF QUALITY SYSTEMS FOR VACCINES PRODUCTION: CIGB AS CASE STUDY
(Yair Quiñones, CIGB. Cuba)
16.15-16.30 CERTIFICATION IN GOOD CLINICAL PRACTICE. IMPLEMENTATION IN PRIMARY HEALTH
CARE (Lidice Fernández, CECMED. Cuba)
16.30-17.00 DISCUSSION
SYMPOSIUM COMBINED VACCINES (Room 3)
THURSDAY 18 (09:00-13:00)
Topic: Pertussis Vaccine
Chairs: Coenraad Hendriksen (Intravacc, The Netherlands) / Mario Landys Chovel (Finlay
Institute, Cuba)
09:00-09:05 OPENING SESSION
09:05-09:35 WHOLE-CELL AND ACELULAR PERTUSSIS COMPONENTS AND INTERACTIONS WITH
OTHER ANTIGENS IN VACCINES COMBINATIONS (Waldely O. Dias, Butantan, Brazil) /
09:35-10:05 ACELULAR VERSUS WHOLE-CELL PERTUSSIS VACCINES: CLINICAL ISSUES (Joseph
Mathew. India)
10:05-10:30 THE CONSISTENCY APPROACH IN LOT RELEASE TESTING OF VACCINES (Coenraad
Hendriksen, Intravacc. The Netherlands)
10:30-10:55 PRODUCT CHARACTERIZATION AND IMMUNOPROTEOMIC PROFILING ARE VALUABLE
TOOLS IN THE DEVELOPMENT AND PRODUCTION OF PERTUSSIS WHOLE CELL AND OMV VACCINES
(Arno van der Ark, Intravacc. The Netherlands)
10:55-11:20 ASSESSMENT OF THE BORDETELLA PERTUSSIS BPCNIC0311 AS PRODUCING STRAIN FOR
GENETICALLY DETOXIFIED TOXOID (PTG), FILAMENTOUS HEMAGGLUTININ (FHA) AND PERTACTIN
TYPE 2 (PRN2) (Anabel Álvarez, CIGB. Cuba)
11:35-12:00 NEW RECOMBINANT HYBRID PROTEINS FROM PERTACTIN TYPE 1 AND 2 OF
BORDETELLA PERTUSSIS (Diógenes Quintana, CIGB. Cuba)
28
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
12:00-12:30 DETECTION AND LOCALIZATION OF THE SURFACE-ASSOCIATED ADHESIN FILAMENTOUS
HAEMAGGLUTIN ON BORDETELLA PERTUSSIS LIVING CELLS USING ATOMIC FORCE MICROSCOPY
(Osvaldo Yantorno, Universidad Nacional de La Plata. Argentina)
12:30-13:00 DISCUSSION
WORKSHOP THERAPEUTIC VACCINES (Cancer, Room 4)
THURSDAY 18 (09:00-13:00)
Topic: Pre-clinic approaches in the design of cancer therapies
Chairs: James Hodge (USA) / Belinda Sánchez (Cuba)
09:00-09:05 OPENING SESSION
09:05-09:35 ATTACKING TUMOR CELLS THAT SURVIVE THERAPY: EXPLOITING IMMUNOGENIC
MODULATION (James Hodge, National Cancer Institute, Maryland. USA)
09:35-10:00 ONGENE ADDICTION: A GOOD REASON FOR DESIGNING THERAPIES BASED ON HER1
AND HER2 (Belinda Sanchez, CENTER OF MOLECULAR IMMUNOLOGY, CUBA. Cuba)
10:00-10:25 PRE-CLINICAL DEVELOPMENT OF SVX-1: A NOVEL THERAPEUTIC CANCER VACCINE
(Ahmed Bouzidi, Vaxeal. Switzerland)
10:25-10:50 EFFECT OF CYCLOOXYGENASE INHIBITION ON THE IMMUNE RESPONSE TO
VACCINATION (Giselle Hevia, Center of Molecular Immunology, Cuba)
10:50-11:15 STATE OF THE ART OF DOWNSTREAM BIOPROCESSING OF PROTEIN BASED BIOLOGICAL
PRODUCTS (Steve Cramer, RPI. USA)
11:15-11:40 DRUGS AGAINST LUNG CÁNCER (Katharine Christine Carter, University of Strathclyde.
UK)
11:40-11:55 DISCUSSION
Topic: A close look into the clinic
Chairs: Marta Ayala (Cuba) / Camilo Rodríguez (Cuba)
11:55-12:20 DECIPHERING THE THERAPEUTIC EFFECT OF NGCGM3/VSSP VACCINE USING A
RELEVANT SPONTANEOUS METASTASIS TUMOR MODEL (Mayrel Labrada, CENTER OF MOLECULAR
IMMUNOLOGY. Cuba)
12:20-12:45 IMMUNOGENICITY OF CIMAVAX-EGF AFTER COMBINATION WITH DIFFERENT
CHEMOTHERAPY SCHEDULES IN ADVANCED NON SMALL CELL LUNG CANCER (Camilo Rodríguez,
Center of Molecular Immunology, Cuba)
12:45-13:10 IMMUNE RESPONSE IN HUMAN AFTER VACCINATION WITH A MODIFIED VARIANT OF
HUMAN VEGF (Marta Ayala, CIGB. Cuba)
29
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
13:10-13:35 RESULTS OF A RANDOMIZED, MULTICENTER AND PLACEBO-CONTROLLED CLINICAL
TRIAL WITH RACOTUMUMAB-ALUM AS SWITCH MAINTENANCE THERAPY IN ADVANCED NON
SMALL CELL LUNG CANCER (Annet Valdes, Center of Molecular Immunology, Cuba)
WHIV: WORKSHOP HIV-AIDS (Room 7)
TUESDAY 16 (09:00-13:30)
Topic: HIV/AIDS
Chairs: José Alcamí, Instituto de Salud Carlos III (Spain) / Vivian Kourí, IPK (Cuba)
09.00-09.05 OPENING SESSION (Vivian Kourí, Cuba)
09.05-09.45 PHARMACOLOGICAL STRATEGIES TO TACKLE THE HIV RESERVOIRS: TO ACTIVATE OR TO
DEACTIVATE (José Alcamí, Instituto de Salud Carlos III. Spain)
09.50-10.10 RESULTS OF CUBAN RESPONSE TO HIV/AIDS EPIDEMIC 28 YEARS AFTER. WERE WE IN THE
RIGHT PATH? (José Joanes, MINSAP. Cuba)
10.15-10.35 PREVENTION OF HIV WITH THE ART TREATMENT IS POSSIBLE. NATIONAL RESPONSE OF
HIV EPIDEMICS IN CUBA (Jorge Pérez, IPK. Cuba)
10.40-11.00 HIGH FREQUENCY OF ANTIVIRAL DRUG RESISTANCE AND NON-B HIV-1 SUBTYPES IN CUBA
(Vivian Kourí, IPK. Cuba)
11.05-11.25 HIV RESISTANCE TO ANTIRETROVIRALS IN ECUADOR (Manuel González, INSPI. Ecuador)
11.30-11.50 HIV VIF AS TARGET FOR ANTI-RETROVIRAL THERAPY. GENERATION OF SINGLE CHAIN
ANTIBODY FRAGMENTS DERIVED FROM A NOVEL MONOCLONAL ANTIBODY AGAINST RECOMBINANT
VIF (Carlos A. Duarte, CIGB, Cuba)
11.55-12.15 CIGB-210: A NOVEL APPROACH TO TREAT HIV INFECTION (Celia Fernández-Ortega, CIGB, Cuba)
12.20-12.40 DETERMINANTS OF ADHERENCE TO HIGHLY ACTIVE ANTIRETROVIRAL THERAPY AMONG
PEOPLE ATTENDING A PUBLIC HIV CLINIC IN GHANA (Nora Katende-Kyenda, South Africa)
12:45-13:05 OXIDANT /ANTIOXIDANT STATUS AND PROGRESSION MARKERS IN HIV/AIDS PATIENT’S
BLOOD SAMPLES IN DIFFERENT CLINICAL CONDITIONS AND ANTIRETROVIRAL COMBINATION (Lizette
Gil, IPK, Cuba)
SYMPOSIUM COMBINED VACCINES (Room 4)
WEDNESDAY 17 (15:00-18:00)
Chairs: Dorothea Sesardic (UK) / Verena Muzio (Cuba)
15:00-15:30 BIOASSAYS FOR EVALUATION OF MEDICAL PRODUCTS DERIVED FROM BACTERIAL
TOXINS (Dorothea Sesardic, NIBSC. UK)
30
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
15:35-15:55 INACTIVATED POLIO VACCINE COMPONENT AND INTERACTIONS WITH OTHER
ANTIGENS IN VACCINES COMBINATIONS (Javier Martin, NIBSC. UK)
16:00-16:20 CUBAN PENTAVALENT VACCINE: CLINICAL ISSUES (Verena Muzio, CIGB. Cuba)
16:25-16:45 COMPARISON BETWEEN WHO AND FDA POTENCY METHODS FOR DIPHTHERIA AND
TETANUS COMPONENTS IN THE CUBAN PENTAVALENT VACCINE (Mabel Izquierdo, CIGB. Cuba)
16:50-17:10 EFFICIENT MEANS TO DETERMINE THE HIB COMPONENT IN LIQUID FORMULATION
VACCINE COMBINATIONS (Ute Rosskopf, WHO. Germany)
17:10-17:30 DISCUSSION
SYMPOSIUM TB VACCINES (Room 5)
MONDAY 15 (15.00-18.00)
Topic: Tuberculosis Vaccine and Research
Chairs: Dr. Willem Hanekom (South Africa) / Prof. Herve Bercovier (Israel)
15:00-15:10 OPENING SESSION
15:10-15:35 DEVELOPING NEW VACCINES FOR TUBERCULOSIS CHALLENGES AND STRATEGIES (Lewis
Schrager, AERAS. USA)
15:35-16:00 TB VACCINES: WHAT IS NEW? (Willem Hanekom, Bill and Melinda Gates Fundation.
South Africa)
16:00-16:25 BACILLE CALMETTE- GUERIN (BCG): A VACCINE GOOD FOR ONLY TB? (Prof. Hervé
Bercovier, Hebrew University of Jerusalem. Israel)
16:25-16:50 TUBERCULOSIS AND SOCIAL INEQUALITIES IN HEALTH (Edilberto González Ochoa,
Tropical Medicine Institute IPK, Cuba)
16:50-17:15 IMMUNOGENICITY AND PROTECTION INDUCED BY A MYCOBACTERIUM TUBERCULOSIS
SIGE/FADD26 DOUBLE MUTANT IN A BALB/C MOUSE MODEL OF PROGRESSIVE PULMONARY
TUBERCULOSIS (Rogelio Hernández-Pando, INCMNSZ, Mexico)
17:15-17:25 MYCOBACTERIUM SMEGMATIS: A PROPHYLACTIC PROTECTIVE CANDIDATE AGAINST TB
IN AN EXPERIMENTAL MODEL OF INFECTION (Nadine Alvarez, Finlay Institute. Cuba)
17:25-17:35 THE DEVELOPMENT OF FERMENTATION AND PURIFICATION PROCESSES FOR THE
RECOMBINANT PROTEIN RV2626C OF MYCOBACTERIUM TUBERCULOSIS EXPRESSED IN
STREPTOMYCES LIVIDANS (Emmanuel N. King-Batsios, PhD student. Ghana)
17:35-17:45 PROTECTIVE CAPACITY OF PROTEOLIPOSOMES FROM MYCOBACTERIUM BOVIS BCG IN
A MOUSE MODEL OF TUBERCULOSIS (Yanely Tirado, Finlay Institute. Cuba)
31
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
17:45-17:55 RELEVANT ASPECTS OF THE USE OF MYCOBACTERIUM ´HABANA´ AS TUBERCULOSIS
VACCINAL CANDIDATE (Iliana Valdes, Tropical Medicine Institute IPK. Cuba)
17.55-18.10 DISCUSSION
SYMPOSIUM VETERINARY VACCINES (Room 6)
MONDAY 15 (15:00-18:00)
Chairs: Ángel Hilario Álvarez (México) / Octavio Fernández Lima (Cuba)
15:00-15:05 OPENING SESSION
15:05-15:25 LONG-TERM VIABILITY MB2054C, MB2057C, AND MB2660C PROTEINS FROM
MYCOBACTERIUM BOVIS INDUCE HUMORAL AND CELLULAR IMMUNE RESPONSES IN VIVO AND IN
VITRO (Ángel Hilario Álvarez, Centro de Investigación y Asistencia en Tecnología y diseño del Estado
de Jalisco. México)
15:25-15:45 INFLUENCE OF ENROFLOXACIN GIVEN IN THERAPEUTIC DOSES ON THE POSTVACCINAL
IMMUNE RESPONSE IN PIGS (Malgorzata Pomorska, National Veterinary Research Institute. Poland)
15:45-16:05 IDENTIFICATION OF IMMUNOGENIC PROTEINS FROM OVARIAN TISSUES OF THE CATTLE
TICK RHIPICEPHALUS (BOOPHILUS) MICROPLUS BY AN IMMUNOPROTEOMIC APPROACH (Patricia
Ramírez, Centro de Investigación y Asistencia en Tecnología y diseño del Estado de Jalisco. México)
16:05-16:25 MOLECULAR CHARACTERIZATION OF THE VITELLOGENIN 3 GENE FROM A MEXICAN
RHIPICEPHALUS (BOOPHILUS) MICROPLUS TICK STRAIN (Moisés Martínez, Centro de Investigación y
Asistencia en Tecnología y diseño del Estado de Jalisco. México)
16:25-16:45 IMPLEMENTATION OF THE CUBAN GUIDES FOR GOOD CLINICAL VETERINARY PRACTICE
BY CENSA (Octavio Fernández Lima, CENSA. Cuba)
16:45-17:05 DESIGN AND OPTIMIZATION OF PURIFICATION PROCESS OF MY32LS PROTEIN
SOLUBILIZING INCLUSION BODIES FOR A NEW VACCINE AGAINST SEA LICE (Carlos Perez, CIGB
Camaguey. Cuba)
17:05-17:25 MOLECULAR CLONING AND EXPRESSION OF GENE FRAGMENTS FROM COMPUTATIONALLY
PREDICTED MYCOPLASMA GALLISEPTICUM SURFACE ANTIGENIC PROTEINS (Jose Antonio Agüero
CENSA. Cuba)
17:25-17:40 DISCUSSION
32
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
SYMPOSIUM BIOPROCESSES (Room 6)
TUESDAY 16 (09.00-13.30)
Topic: Upstream Bioprocesses
Chairs: Miguel A. Jácome Vital, CINESTAV-IPN (México) / Odalys Ruíz, CIGB (Cuba)
09.00-09.05 OPENING SESSION (Odalys Ruíz, Cuba)
09.05-09.35 CHARACTERIZATION OF MICROBIAL CULTURES IN A HIGH-THROUGHPUT 24-WELL
MICROBIOREACTOR SYSTEM BY RESPIROMETRY (Miguel A. Jácome Vital, CINESTAV-IPN. México)
09.40-10.10 CHARACTERIZATION OF A BIOREACTOR FOR CANCER VACCINE DEVELOPMENT, BASED
ON HER-1 EXTRACELLULAR DOMAIN, WITH CFD AID (Osmán Fernández, CENTER OF MOLECULAR
IMMUNOLOGY. Cuba).
10.15-10.45 STRATEGIES FOR REDUCTION OF BIOREACTOR CONTAMINATIONS AND ENHANCED
PRODUCTIVITY IN INDUSTRIAL FERMENTATIONS. PRODUCTION OF HBSAG IN PICHIA PASTORIS
FERMENTATION AS CASE OF STUDY (Juan Miguel Rivera, CIGB. Cuba)
10.50-11.20 ADENOVIRAL PARTICLES AS VECTORS FOR GENE THERAPY AND VACCINE TECHNOLOGY:
AN INTEGRAL PERFORMANCE FOR PRODUCTION (Angélica Meneses, Morelos University. México)
11.25-11.35 DISCUSSION
11.35-12.05 STATISTICAL APPROACHES TO DEFINE MEDIUM COMPOSITION FOR BIOMASS PRODUCTION
OF RECOMBINANT E.COLI CELLS TO OBTAIN A THERAPEUTIC VACCINE (Odalys Ruíz, CIGB. Cuba)
12.10-12.40 THE CHARACTERISTICS OF VIRUS REMOVAL FILTERS WITH DIFFERENT MEMBRANE
MATERIALS AND STRUCTURES (Roya Dayani, Asahi Kasei Bioprocess Europe. Belgium)
12.45-13.00 PALL CAPABILITIES FOR THE BIOTECH INDUSTRY (Gina Meza, Sistemas Industriales de
México, S.A. de C.V. México. México)
TUESDAY 16 (15:00-18:00)
Topic: Downstream Bioprocesses, high throughput technologies
Chairs: Nika Lendero, BIASeparations (Slovenia) / Rodolfo Valdés, CIGB (Cuba)
15.00-15.30 USING MONOLITHIC CHROMATOGRAPHIC COLUMNS TO CONTROL DE
BIOPHARMACEUTICAL MANUFACTURING PROCESS (Nika Lendero, BIASeparations. Slovenia)
15.35-16.05 EVALUATION OF A PROCESS REDESIGN FOR THE PURIFICATION OF A RECOMBINANT
STREPTOKINASE USING CIM QA MONOLITHIC COLUMN (Gabriel Márquez, CIGB. Cuba)
16.10-16.40 IMMUNOAFFINITY CHROMATOGRAPHIC MONOLITHS FROM ANALYTICS TO DOWNSTREAM
(Nika Lendero, BIASeparations. Slovenia)
33
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
16.45-17.15 MONOLITHIC STRUCTURE SUPPORT APPLICATION FOR IMMUNOPURIFYING HEPATITIS B
SURFACE ANTIGEN PARTICLES FOR HUMAN VACCINATION (Rodolfo Valdés, CIGB. Cuba)
17.20-17.50 BATCH OR CONTINUOUS CHROMATOGRAPHY? WHICH CHROMATOGRAPHIC METHOD DO
YOU CHOOSE? (Ulrike Maschke, KNAUER. Germany)
17.55-18.00 CONCLUSIONS
SYMPOSIUM BIOPROCESSES (Room 6)
WEDNESDAY 17 (09.00-13.30)
Topic: Downstream Bioprocesses
Chairs: Steve Cramer, RPI (USA) / Miladys Limonta, CIGB (Cuba)
09.00-09.05 OPENING SESSION (Miladys Limonta)
09.05-09.35 UNDERSTANDING AND ENHANCING SELECTIVITY IN MULTIMODAL CHROMATOGRAPHY
FOR COMPLEX PROTEIN SEPARATIONS (Steve Cramer, RPI. USA)
09.40-10.10 PURIFICATION OF ACTIVE INGREDIENTS: A TRANSFER FROM BATCH TO CONTINUOUS
COUNTERCURRENT MULTICOLUMN CHROMATOGRAPHY PROCESSES (Ulrike Maschke, KNAUER.
Germany)
10.15-10.45 DESIGNING AND KNOWING THE SPACE FOR CIGB 550-E7, AN ACTIVE PHARMACEUTICAL
INGREDIENT FOR HPV CANDIDATE VACCINE (Miladys Limonta, CIGB. Cuba)
10.50-11.20 VIRUS FILTRATION PROCESS DESIGN: MAXIMIZING VIRUS RETENTION BY SIMPLE
PARAMETER ADJUSTMENTS (Sebastian Teitz, Asahi Kasei Bioprocess Europe. Germany)
11.25-11.35 DISCUSSION
11.35-12.05 VSSP PRODUCTIVE PROCESS FROM SYNTHETIC GANGLIOSIDE (Lourdes Hernández, CENTER
OF MOLECULAR IMMUNOLOGY. Cuba)
12.10-12.40 PLASMA FRACTIONATION USING SIMULATED MOVING BED TECHNOLOGY (SMB) (Ulrike
Maschke, KNAUER. Germany)
12.45-13.00 CONCLUSIONS
WEDNESDAY 17 (15.00-18.00)
Topic: Drug delivery Bioprocesses
Chairs: Valerie Ferro, SIPBS (UK) / Lissette Agüero, BIOMAT (Cuba)
15.00-15.30 CHALLENGES IN DEVELOPING MUCOSAL VACCINES (Valerie Ferro, SIPBS. UK)
34
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
15.35-16.05 CATIONIC PH-RESPONSE MICROPARTICLES AS DEVICE FOR COLON SPECIFIC DELIVERY
(Lissette Agüero, BIOMAT. Cuba)
16.10-16.40 TECHNOLOGICAL DEVELOPMENT OF PEGYLATED BIOPHARMACEUTICAL PRODUCTS. CASES
OF STUDY IN THE CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY (CIGB) (Liurdis Caballero,
CIGB. Cuba)
16.45-17.15 SYNTHESIS OF FLUORESCENT NANOPARTICLES OF PEG-PLA COPOLYMERS BY UGI FOUR
COMPONENT CONDENSATION (Marcos López, Universidade Federal do Rio de Janeiro, Instituto de
Macromoléculas. Brasil)
17.20-17.50 NANOSCOPIC STUDIES TO TRACK THE EFFECTS OF NEXT-GENERATION NANOMEDICINES
ON PATIENTS (Dimitrios Lamprou, SIPBS. UK)
17.55-18.00 CONCLUSIONS
35
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
POSTERS SESSIONS
Wednesday 17 (15:00-18:00)
SYMPOSIUM MENINGOCOCCAL VACCINES
Chairs: Caridad Zayas (Finlay Institute) and Fidel Ramírez (Finlay Institute)
01: STANDARDIZATION OF AN ELISA FOR DETERMINING CONTENT OF POLYSACCHARIDES A, C, Y, W
IN MULTIVALENT VACCINES
Fernández Y, Gutiérrez N, Lara M, Corcho L, Alfonso S, Chovel ML.
FINLAY INSTITUTE, HAVANA, CUBA
02: NEISSERIA MENINGITIDIS SEROGROUP X: NEW VACCINE STRATEGIES
Zayas C, Acevedo R, Gunnstein, García L, Valmaseda T, Cedré B, Cuello M, et al.
FINLAY INSTITUTE, HAVANA, CUBA
03: NEW PURIFICATION TECHNOLOGY TO OBTAIN MENINGOCOCCAL POLYSACHARIDES FROM
SEROGROUPS A, C, Y, W AND X
González H, González D, Hernández M, Guerra M, Concepción F, Guzmán LA, Martínez JC et al.
FINLAY INSTITUTE, HAVANA, CUBA
04: RETROSPECTIVE VALIDATION OF THE PROCESS FOR OBTAINING THE SEROGROUP B NEISSERIA
MENINGITIDIS OUTER MEMBRANE VESICLES
Lozada SL, Bayolo J, Rojo D, Soto C, Aguiar S, Troya Y and Merladet Y.
FINLAY INSTITUTE, HAVANA, CUBA
05: SELECTION OF NEISSERIA MENINGITIDIS SEROGROUP Y STRAINS AS TARGET OF BACTERICIDAL
ACTIVITY IN THE EVALUATION OF MENINGOCOCCAL VACCINES
Callis AH. Cedré B, Acevedo R, García M, Cardoso F, Núñez D, García L.
FINLAY INSTITUTE, HAVANA, CUBA
06: SURVEILLANCE OF AGENTS THAT CAUSE BACTERIAL MENINGITIS IN CUBA BY PCR
Gutiérrez O, Feliciano O, Vásquez V, Rodríguez N, Llanes R.
TROPICAL MEDICINE INSTITUTE «PEDRO KOURÍ» (IPK), HAVANA, CUBA
07: DEVELOPMENT A NEOGLYCOCONJUGATE VACCINE FROM NEISSERIA MENINGITIDIS
SEROGROUP X
Cardoso F, Glez M, Garrido R, Baró B, Aliaga I, Rey E. D, Acevedo R.
FINLAY INSTITUTE, HAVANA, CUBA
36
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
08: DEVELOPMENT OF INDIRECT ELISAS FOR EVALUATING HUMAN IGG ANTIBODIES AGAINST OUTER
MEMBRANE VESICLES OF NEISSERIA MENINGITIDIS SEROGROUPS A AND W
Aranguen Y, Balboa JA, Álvarez M, García LG, Cedré B, Naess L, Mandiarote A et al.
FINLAY INSTITUTE, HAVANA, CUBA
09: NEISSERIA MENINGITIDIS DERIVED PROTEOLIPOSOME AS AN ADJUVANT FOR ALLERGEN
VACCINES
Ramírez W, Labrada A, Facenda E, Bourg V, González B, Más A et al.
NATIONAL CENTER OF BIOPRODUCTS (BIOCEN), ARTEMISA, CUBA
10: METHODOLOGY FOR THE MONITORING OF CHEMICAL STANDARDS FOR VACCINES BY COMBINING
SHELF-LIFE STABILITY AND SYSTEMATIC IN-USE RESULTS
Díaz D, Chovel ML, Lara D, Alfonso S.
FINLAY INSTITUTE, HAVANA, CUBA
11: CHARACTERIZATION OF AN IN-HOUSE POLYSACCHARIDE A STANDARD FOR QUALITY CONTROL
TESTING OF MENINGOCOCCAL VACCINES
Gutiérrez N, Chovel ML, Díaz D, Lara D.
FINLAY INSTITUTE, HAVANA, CUBA
12: NEUMOCOCCAL MENINGOENCEFALITIS, A REASON FOR A PREVENTIVE VACCINE
Pantoja O, Álvarez I, Luis I, Rivero M, Luis MC.
Hospital Pediátrico Universitario «William Soler»
13: CHARACTERIZATION OF CAPSULAR POLYSACCHARIDES STANDARDS FOR THE QUALITY CONTROL
OF MENINGOCOCCAL VACCINES
Alfonso S, Chovel ML, Díaz D, Gutiérrez N, Tamayo Y.
FINLAY INSTITUTE, HAVANA, CUBA
SYMPOSIUM ENTERIC VACCINE
Chairs: Sonsire Fernández and Jose Luis Pérez
14: PRECLINICAL EVALUATION: TOXICITY OF SINGLE DOSE OF THE VACCINE TYPHOID OF
POLYSACCHARIDE VI CONJUGATE IN SPRAGUE DAWLEY RATS
Oliva R, Fariñas M, Infante JF, González MO, Hernández T, Núñez D, Pérez V, Valdés BY, Aranguren Y,
Bacallao EG, Campos L, Fernández S.
FINLAY INSTITUTE, HAVANA, CUBA
37
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
15: MONITORING OF THE CONTROLED WITH PLACEBO, RANDOMIZED AND DOUBLE BLIND
PHASE I CLINICAL TRIAL TO ASSESS SAFETY, REACTOGENICITY AND IMMUNOGENICITY, OF THE CV
638 HEALTLY CHILDREN AND ADOLESCENTS IN CUBA
García HM, Valera RF, Pérez JE, Fando R, Cardoso E, Armesto MI et al.
FINLAY INSTITUTE, HAVANA, CUBA
16: CHARACTERIZATION OF MURINE MONOCLONAL ANTIBODY TO CAPSULAR POLYSACCHARIDE
FROM SALMONELLA TYPHI AND ITS POTENCIAL USE IN QUANTIFICATION OF TYPHOID VACCINES
Amin N, Reyes F, Camacho F, Cuello M, Otero O, Núñez D, Ochoa R, Fernández S, García L, Cardoso D.
FINLAY INSTITUTE, HAVANA, CUBA
17: COMPARISON OF TWO VIBRIOCIDAL ASSAYS TO EVALUATE THE IMMUNOGENICITY OF
CHOLERA VACCINES
Cedré B, García M, Landys M, Tamayo Y, Lisbeth N, Mandariaga S, Acevedo R, García L.
FINLAY INSTITUTE, HAVANA, CUBA
18: MONOCLONAL ANTIBODY AGAINST VIBRIO CHOLERAE O1 LIPOPOLYSACCHARIDE COUPLED TO
LATEX PARTICLES. A TOOL FOR THE RAPID DIAGNOSIS OF CHOLERA DISEASE
Otero O, Cuello M, Reyes F, Camacho F, Duranti G, Morales MM, Mora R.
FINLAY INSTITUTE, HAVANA, CUBA
19: PHYSICOCHEMICAL AND IMMUNOLOGICAL CHARACTERIZATION OF VI POLYSACCHARIDE
CONJUGATED TO TETANUS TOXOID
Soubal JP, Santana D, Espinosa C, Garrido R, Pedroso J, Torres L.
FINLAY INSTITUTE, HAVANA, CUBA
20: CHEMICAL ANALYSIS OF O-ANTIGEN DERIVED LPS FROM SALMONELLA PARATYPHI A
Hernández M, Pérez JL, Blain K, Fernández S, Martínez M, Lescaille D and col.
FINLAY INSTITUTE, HAVANA, CUBA
21: PURIFICATION AND PRELIMINARY CHARACTERIZATION OF OMV DERIVED FROM OUTER
SURFACE OF SALMONELLA PARATYPHI A
Pérez JL, Fernández S, Martínez M, Blain K, Lescaille D, Serrano D and col.
FINLAY INSTITUTE, HAVANA, CUBA
22: PURIFICATION OF O-ANTIGEN DERIVED LPS FROM SALMONELLA PARATYPHI A
Pérez JL, Blain K, Fernández S, Martínez M, Lescaille D, Serrano D and col.
FINLAY INSTITUTE, HAVANA, CUBA
38
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
23: IMMUNOGENICITY OF VI POLYSACCHARIDE OF SALMONELLA TYPHI CONJUGATED TO
DIPHTHERIA TOXOID
Soroa Y, Fernández S, Rodríguez L, Rodríguez Y, Martin Y, Soubal JP.
FINLAY INSTITUTE, HAVANA, CUBA
24: CHARACTERIZATION OF STANDARDS FOR THE QUANTIFICATION OF POLYSACCHARIDE IN A
CONJUGATE SALMONELLA VACCINE
Lara D, Chovel ML, Diaz D, Gutiérrez N.
FINLAY INSTITUTE, HAVANA, CUBA
SYMPOSIUM PNEUMOCOCCAL VACCINES
Chairs: Indira Utria and Laura Rodríguez
25: THE CONJUGATE SYNTHESIS WITH A LONG SPACER ARM INCREASES THE IMMUNOGENICITY
OF PNEUMOCOCCAL SEROTYPE 5 POLYSACCHARIDE CONJUGATE VACCINE
Santana D, Felipe J, Valdés Y, Soroa Y, Soubal JP, Aleaga I.
FINLAY INSTITUTE, HAVANA, CUBA
26: DEVELOPMENT AND VALIDATION OF ELISA FOR QUANTITATIVE SEROTYPE SPECIFIC
POLYSACCHARIDE IGG OF STREPTOCOCCUS PNEUMONIAE IN RABBIT SERUM
Rodríguez LM, Martín Y, Pérez A, Espinosa-Viñals C, García-Rivera D, Travieso M, Nicot M.
FINLAY INSTITUTE, HAVANA, CUBA
27: DESIGN AND MANUFACTURE OF ANTIGEN-DISPLAYING POLYHYDROXYALKANOATE BEADS AS
NOVEL PARTICULATE VACCINE TO PREVENT PNEUMOCOCCAL AND MENINGOCOCCAL DISEASES
González M, Rodríguez L, Vérez V, Rehm H.
FINLAY INSTITUTE, HAVANA, CUBA
28: PHASE I CLINICAL TRIAL OF A CUBAN 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN
HEALTHY INFANTS
González N, Paredes B, Dotres CP, Puga R, Ricardo Y, García Y, del Valle RA et al.
FINLAY INSTITUTE, HAVANA, CUBA
29: RELEVANCE OF O-ACETYL AND PHOSPHOGLYCEROL GROUPS FOR THE ANTIGENICITY OF
STREPTOCOCCUS PNEUMONIAE SEROTYPE 18C CAPSULAR POLYSACCHARIDE
Chang J, Serrano Y, Garrido R, Rodríguez L. M, Pedroso J, Cardoso F et al.
FINLAY INSTITUTE, HAVANA, CUBA
39
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
30: VALIDATION OF ANALYTICAL PROCEDURES FOR QUALITY CONTROL OF PNEUMOCOCCAL
VACCINE QUIMI-VIO BY HPLC
Pedroso J, Aliaga I, Rodríguez E, Villar A, Ramírez U, Santana D, García D, Valdés Y, Vérez V.
FINLAY INSTITUTE, HAVANA, CUBA
31: DEVELOPMENT OF A DECAVALENT CONJUGATE VACCINE AGAINST STREPTOCOCCUS
PNEUMONIAE
Mariño D, Chang J, Santana D, Herrera L, Carrera M, Pérez A, Fonseca D et al.
FINLAY INSTITUTE, HAVANA, CUBA
32: VALIDATION AND CONFIRMATION OF THE WHO RECOMMENDED ELISA FOR QUANTITATION
OF IGG AGAINST POLYSACCHARIDES 1, 5, 6A, 6B, 14, 19A, 19F AND 23F OF STREPTOCOCCUS
PNEUMONIAE IN HUMAN SERA, AT IMMUNOLOGY LABORATORY FROM CENTER FOR
BIOMOLECULAR CHEMISTRY
Pérez A, Rodríguez LM, Garcés A, Martínez D, Espinosa-Viñals C, Soroa Y.
FINLAY INSTITUTE, HAVANA, CUBA
33: CHARACTERIZATION OF STRAINS OF STREPTOCOCCUS PNEUMONIAE SEROTYPE 7F, 9V AND 19
A AS FUTURE VACCINE CANDIDATES.
Hernández M, González H, Guerra M, Guzmán L.A, Martínez J. C, Concepción F, Costa W et al.
FINLAY INSTITUTE, HAVANA, CUBA
34: PHYSICOCHEMICAL CHARACTERIZATION OF «IN-HOUSE» ALUMINUM PHOSPHATE ADJYVANT
USED IN THE FORMULATION OF CUBAN PNEUMOCOCCAL VACCINE: QUIMI-VIO
Fonseca D, Reguera E, Nadal L, Felipe J, Arias D, Triana L.
FINLAY INSTITUTE, HAVANA, CUBA
35: COMPLICATED COMMUNITARIAN PNEUMONIA. CLINICAL EVOLUTION MICROBIOLOGICAL
ISOLATION AND ANTIBIOTIC COST. WILLIAM SOLER HOSPITAL. 2013-2014
Sánchez C, Ramos LT, Reyes C, Barreiro B, Cantillo H and Martínez I.
Pediatric Hospital «William SoIer»
36: SENTINEL SURVEILLANCE OF PNEUMOCOCCAL DISEASE AND NASOPHARYNGEAL
COLONIZATION: STRATEGY FOR MONITORING THE EFFECTIVENESS AND IMPACT OF THE
HEPTAVALENT PNEUMOCOCCAL CUBAN VACCINE.
Linares N, Toraño G, Fonseca M, Dotres CP, Reyes A, Montes de Oca M.
FINLAY INSTITUTE, HAVANA, CUBA
40
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
SYMPOSIUM VIRAL VACCINES
Chairs: Ana Beatriz Pérez (IPK) and Ernesto Marcos (CIGB)
37: INDUCTION OF NEUTRALIZING ANTIBODIES AND MULTI-SPECIFIC CELLULAR IMMUNE
RESPONSE EMPLOYING A CHIMERIC PROTEIN ENCOMPASSING HEPATITIS C VIRUS EPITOPES
Aguilar D, Dueñas S, Álvarez L, Santana FL, Dubuisson J, Wychowski C et al.
CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA
38: A TETRAVALENT DENGUE VACCINE CONTAINING A MIX OF DOMAIN III-P64K AND DOMAIN IIICAPSID PROTEINS INDUCES A PROTECTIVE RESPONSE IN MICE
Izquierdo A, García A, Lazo L, Gil L, Álvarez M, Hermida L, Guillén G, Guzmán MG.
TROPICAL MEDICINE INSTITUTE «PEDRO KOURÍ» (IPK), HAVANA, CUBA
39: POLYHISTIDINE TAG LOCATION TRIGGER DIFFERENTIATED EXPRESSION LEVELS OF DENGUE 2
VIRUS RECOMBINANT NS3 PROTEIN IN ESCHERICHIA COLI
Falcón R, Ramírez R, Hernández MS, Fleitas O, Almaguer T, Ortega O, et al.
TROPICAL MEDICINE INSTITUTE «PEDRO KOURÍ» (IPK), HAVANA, CUBA
40: ROLE OF CC CHEMOKINE RECEPTOR 1 AND TWO OF ITS LIGANDS IN HUMAN DENGUE
INFECTION. THREE APPROACHES UNDER THE CUBAN SITUATION
Sierra B, Pérez, AB, García G, Aguirre E, Álvarez M, González D, Guzmán MG.
TROPICAL MEDICINE INSTITUTE «PEDRO KOURÍ» (IPK), HAVANA, CUBA
41: DEVELOPMENT OF TWO NOVEL TECHNOLOGIES TO FOLLOW UP THE HBV THERAPEUTIC
VACCINATION: QUANTIFICATION AND GENOTYPING OF HBV-DNA FROM HUMAN SERUM
Aguiar J, Aguilar JC, Rodríguez L, Freire F, Montalvo MC, León Y, Pujol F, Loureiro C, Muzio V, Pentón
E, Guillén G.
CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA
42: OCCULT HEPATITIS B VIRUS INFECTION IN CHILDREN BORN TO HBSAG-POSITIVE MOTHERS
WITH ACTIVE-PASSIVE IMMUNIZATION
Bello M, Rodríguez L, Rodríguez D, Montalvo MC, Pedroso P, Sariego S, Sánchez M, Naranjo N,
Moyano S.
TROPICAL MEDICINE INSTITUTE «PEDRO KOURÍ» (IPK), HAVANA, CUBA
43: PREVALENCE OF ROTAVIRUS GENOTYPES IN CHILDREN YOUNGER THAN 5 YEARS OF AGE,
BEFORE THE INTRODUCTION OF A UNIVERSAL ROTAVIRUS VACCINATION PROGRAM
Tejero Y, Ribas MA, León MA, Cordero Y, Ramírez Y, Pérez D, Roque R.
TROPICAL MEDICINE INSTITUTE «PEDRO KOURÍ» (IPK), HAVANA, CUBA
41
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
44: HBV AND HCV MUTANTS ASSOCIATE WITH VACCINE ESCAPE AND ANTIVIRAL RESISTANCE
Rodríguez L, Montalvo MC, Bello M, Pérez A, Moyano S.
TROPICAL MEDICINE INSTITUTE «PEDRO KOURÍ» (IPK), HAVANA, CUBA
45: EVALUATION OF HUMORAL RESPONSE TO HEBERBIOVAC HB IN HAEMODIALYSIS PATIENTS
FROM HAVANA CITY
Montalvo MC, Bello M, Delgado G, Díaz M, Rodríguez L.
TROPICAL MEDICINE INSTITUTE «PEDRO KOURÍ» (IPK), HAVANA, CUBA
46: MOLECULAR EPIDEMIOLOGY OF HUMAN PAPILLOMAVIRUS INFECTIONS IN CUBAN
POPULATION
Soto Y, Limia CM, Kourí V, Goicolea A, Torres G, García Y, López MV, Blanco OA et al.
TROPICAL MEDICINE INSTITUTE «PEDRO KOURÍ» (IPK), HAVANA, CUBA
47: BROAD AND FUNCTIONAL T CELL IMMUNE RESPONSE FOLLOWING IMMUNIZATION WITH
HEPATITIS C VIRUS PROTEINS-BASED VACCINE FORMULATED WITH POLYESTER BEADS
Piniella B, Amador-Cañizares Y, Álvarez-Lajonchere L, Pérez A, Aguilar D, Castañedo Y et al.
CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA
48: HEPATITIS C VIRUS PREVALENCE IN HEMODIALYSIS UNITS IN HAVANA AND ARTEMISA
PROVINCES AND ANTI-HCV HUMORAL IMMUNE RESPONSE
Álvarez-Lajonchere L, Olivera S, Figueredo J, González Y, Cinza Z, Castelo X.
CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA
WTV: WORKSHOP THERAPEUTIC VACCINES (INFECTIOUS DESEASES)
Chairs:
49: SAFETY AND EFFICACY OF TERAP C: A THERAPEUTIC DNA VACCINE PREPARATION AGAINST
HEPATITIS C. PHASE II CLINICAL TRIAL
Dorta Z, Castellanos M, Cinza Z, Dueñas S, Valenzuela C et al.
CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA
50: THE CIGB550 PEPTIDE AS COMPONENT OF HPV THERAPEUTIC VACCINE.
Granadillo M, Alfonso AB, Vallespi MG, Batte A, Soria Y.
CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA
51: CONTINUITY OF A WORKING REFERENCE MATERIAL OF HEPATITIS B CORE ANTIGEN FOR
DEVELOPING A NASAL VACCINE.
Vega M, Rodríguez C, Plá I, García G, Dorta A, Palacio Y, Padrón S.
CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA
42
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
52: HEBERNASVAC, A NOVEL THERAPEUTIC VACCINE CANDIDATE FOR CHRONIC HEPATITIS B:
TOXICOLOGICAL STUDIES.
Aldana L, Cosme K, Bacardí D, Ancizar J, Suárez J, Blanco A, Urquiza D, Castro J, et al.
CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA
53: VALIDATION OF THE METHOD OF HBCAG IMMUNOGENICITY FOR THE THERAPEUTIC VACCINE
HEBERNASVAC
Martínez Y, Valle A, Nuñez Z, Soria Y, Blanco A, Brown E, Izquierdo M, García G, Rosales I et al.
CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA
WRS: WORKSHOP REGULATORY SYSTEM
Chairs: Judith Cartaya and Violeta Rodríguez (CECMED)
54: BIOSIMILARS NON-CLINICAL REGULATIONS: NEW KNOWLEDGE NEW APPRAISAL
Martínez L, Valle E.
NATIONAL CENTRE FOR STATE CONTROL OF DRUGS, EQUIPMENTS AND MEDICAL DEVICES
(CECMED), HAVANA, CUBA.
55: POST APPROVAL CHEMISTRY, MANUFACTURATING AND CONTROL CHANGES IN CUBA WITH A
FOCUS ON BIOPHARMACEUTICALS.
Preval D, Hechavarría Y, Pérez V, Escoto J.
NATIONAL CENTRE FOR STATE CONTROL OF DRUGS, EQUIPMENTS AND MEDICAL DEVICES
(CECMED), HAVANA, CUBA.
56: THE NEW MARKETING AUTHORIZATION REQUIREMENTS FOR BIOLOGICALS PRODUCTS
Pérez R, Pérez V, Hechavarría Y, Orta D and Martínez L.
NATIONAL CENTRE FOR STATE CONTROL OF DRUGS, EQUIPMENTS AND MEDICAL DEVICES
(CECMED), HAVANA, CUBA.
57: SAFETY AND BIOSIMILARITY OF IOR® EPOCIM COMPARED WITH EPREX® BASED ON
TOXICOLOGIC, PHARMACODYNAMIC, AND PHARMACOKINETIC STUDIES IN THE SPRAGUEDAWLEY RAT
Pucaj K, Riddle K, Taylor SR, Ledon N, Bolger GT.
CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA.
58: IMPLEMENTATION OF A REGULATORY SYSTEM FOR THE CONTROL AND AUTHORIZATION OF
BLOOD BANKS IN CUBA
Álvarez MP, Soza A, Claro Y, Scull I, Mesa A.
NATIONAL CENTRE FOR STATE CONTROL OF DRUGS, EQUIPMENTS AND MEDICAL DEVICES
(CECMED), HAVANA, CUBA.
43
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
59: ISOLATION OF MESENCHYMAL STEM CELLS DERIVED FROM ADIPOSE TISSUE.
Galván JA, Miranda A, De León Y, Rondó T, Macías C, del Valle L, González A et al.
HEMATOLOGY INSTITUTE, HAVANA, CUBA
60: STEM CELL THERAPY FOR DEGENERATIVE DISEASE OF THE KNEE JOINT
Baganet A, Fernández N, Forrellat M, Hernández P, Macías C, Galván J, González A, Lam R, del Valle L.
HEMATOLOGY INSTITUTE, HAVANA, CUBA
61: IMPROVEMENT OF THE VACCINE QUALITY ASSURANCE BY IMPLEMENTING RELEVANT
EFFICIENCY INDICATORS
Martínez R, Candia J, Agüero B, Sartorio J, Mandiarote A, Suárez M, et al.
FINLAY INSTITUTE, HAVANA, CUBA
62: THE CONTAMINATION CONTROL IN THE PRODUCTION OF VACCINES, A GLOBAL APPROACH.
Figueroa R.
NATIONAL CENTRE FOR STATE CONTROL OF DRUGS, EQUIPMENTS AND MEDICAL DEVICES
(CECMED), HAVANA, CUBA.
63: STUDY OF SODIUM AND POTASSIUM IN A TOXICITY TEST REPEATED DOSE OF BIOSIMILAR
CD20 INTRAVENOUSLY IN MACACA FASCICULARIS
González C, Mancebo A, Arteaga ME, González B, Bada AM, Merino N, León A et al.
TROPICAL MEDICINE INSTITUTE «PEDRO KOURÍ» (IPK), HAVANA, CUBA
64: PERSPECTIVES AND PRINCIPLES FOR GENE THERAPY REGULATIONS
Alfonso Y, Hechavarría Y.
NATIONAL CENTRE FOR STATE CONTROL OF DRUGS, EQUIPMENTS AND MEDICAL DEVICES
(CECMED), HAVANA, CUBA.
65: DEVELOPMENT OF REGULATORY SYSTEM OF ORGANS FOR TRANSPLANTATION IN CUBA.
Claro Y, Álvarez MP, Hechavarría Y, Fernández L, Hermida D.
NATIONAL CENTRE FOR STATE CONTROL OF DRUGS, EQUIPMENTS AND MEDICAL DEVICES
(CECMED), HAVANA, CUBA.
66: POINTS TO CONSIDER ON ELECTRONIC DATA COLLECTION IN VACCINE CLINICAL TRIALS. FOCUS
ON CASE REPORT FORMS
Duque E, Orta D, Cartaya J, Fernández L.
NATIONAL CENTRE FOR STATE CONTROL OF DRUGS, EQUIPMENTS AND MEDICAL DEVICES
(CECMED), HAVANA, CUBA.
67: WORLD SCIENTIFIC – TECHNOLOGY TENDENCIES OF THE TREATMENT WITH STEM CELLS.
Cossío G, Cartaya J.
CONSULTANCY BIOMUNDI, HAVANA, CUBA
44
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
68: PERSPECTIVES AND PRINCIPLES FOR GENE THERAPY REGULATIONS
Alfonso Y, Hechavarría Y.
NATIONAL CENTRE FOR STATE CONTROL OF DRUGS, EQUIPMENTS AND MEDICAL DEVICES
(CECMED), HAVANA, CUBA.
69: PENAL RESPONSABILITY IN THE PRODUCTION AND MARKETING OF VACCINES.
López A, López L.
NATIONAL CENTRE FOR STATE CONTROL OF DRUGS, EQUIPMENTS AND MEDICAL DEVICES
(CECMED), HAVANA, CUBA.
SYMPOSIUM COMBINED VACCINES
Chairs:
70: STUDY OF USE OF VACCINE PENTAVALENTE OF TRINIDAD.
Rodríguez A, Ruíz A, Rodríguez. R.
Trinidad Hospital «Tomás Carreras Galiano», Villa Clara, Cuba
71: ASSESSMENT OF THE BORDETELLA PERTUSSIS BPCNIC0311 AS PRODUCING STRAIN FOR
GENETICALLY DETOXIFIED TOXOID (PTG), FILAMENTOUS HEMAGGLUTININ (FHA) AND PERTACTIN
TYPE 2 (PRN2).
Álvarez A, Quintana D, Delgado M, Lemos G, Coizeau E, Ramos R, Tambara Y, González I, et al.
CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA
72: COMPARATIVE RESULTS OF QUANTIFICATION OF PRP IN HEBERPENTA-L VACCINE WITH TWO
HYDROLYSIS METHODS BY USE OF HIGH-PERFORMANCE ANION-EXCHANGE CHROMATOGRAPHY
WITH PULSE AMPEROMETRIC DETECTION (HPAEC-PAD).
Marcelo JL, De Senna L, Costa L, Claudio L, Izquierdo M, Martínez E, Gomes E, Torres M , Denis M,
Akemi D. CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA
73: DEVELOPMENT OF SANDWICH ELISA-BASED METHODS FOR SCREENING BORDETELLA
PERTUSSIS ANTIGENS EXPRESSED IN THE BACTERIAL CELL CULTURE
Lemos G, Delgado M, Quintana D, Coizeau E, Caballero E and Álvarez A.
CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA
74: EVENTS SUPPOSEDLY ATTRIBUTABLE TO VACCINATION OR IMMUNIZATION, LA HABANA,
CUBA, 2010-2014.
Egües LI, Pérez S.
Epidemiology Provincial Centre, La Habana, Cuba
45
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
75: CONCOMITANT ADMINISTRATION OF VACCINES QUIMI-VIO, VA-MENGOC-BC® AND HEBERPENTA® IN RABBITS AS EXPERIMENTAL MODEL
Espinosa C, García D, Rodríguez L, Amador A, Nicot M, Valle L.
FINLAY INSTITUTE, HAVANA, CUBA
76: BEHAVIOUR OF VACCINE ADVERSE REACTIONS IN MTZAS PROVINCE FROM 2009 TO 2012
Marin N, Santos L.
Health Municipal of Matanzas, Matanzas, Cuba
77: VACCINE ADVERSE REACTIONS IN CHILDREN REPORTED BY THE CUBAN SYSTEM
PHARMACOVIGILANCE, 2003-2013
Furones JA, Cruz MA, López AF.
Escuela Nacional de Salud Pública
78: ESTABLISHMENT OF A DIPHTHERIA TOXIN IN-HOUSE STANDARD FOR A VERO TOXICITY
TESTING FOR VACCINES
Herrera L, Chovel ML, Bolaños G, Monteagudo R, Fidalgo O.
FINLAY INSTITUTE, HAVANA, CUBA
79: SHELF-LIFE STABILITY AND SYSTEMATIC IN-USE RESULTS OF A REFERENCE TETANUS ANTITOXIN
FOR THE IN VIVO SERONEUTRALIZATION TEST
Mahy T, Cisneros D, Herrera L, Ontivero I, Chovel ML.
FINLAY INSTITUTE, HAVANA, CUBA
80: PERTUSSIS POTENCY TEST PERFORMANCE ASSESSMENT FOR HEBERPENTA-L VACCINE AS TOOL
FOR ASSAY QUALITY CONTROL
Bourg V, Díaz M, Huergo L, Pérez C.
NATIONAL CENTER OF BIOPRODUCTS (BIOCEN), ARTEMISA, CUBA
81: DESIGN OF HPLC METHOD FOR DETERMINATION OF TOTAL CARBOHYDRATES IN QUIMIHIB
APPLYING QUALITY BY DESIGN
Borrego K, Meneau R, Baeza A, Álvarez A.
NATIONAL CENTRE FOR STATE CONTROL OF DRUGS, EQUIPMENTS AND MEDICAL DEVICES
(CECMED), HAVANA, CUBA.
82: PERTUSSIS SEROLOGICAL POTENCY TEST: LINKS TO THE PROTECTION AND SIGNIFICANCE FOR
VACCINE LOT RELEASE
Chovel ML, Gutiérrez N, Mahy T, Herrera L, Mandiarote A.
FINLAY INSTITUTE, HAVANA, CUBA
46
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
83: PREPARATION OF MASTER AND WORKING CELL BANKS FROM BORDETELLA PERTUSSIS
BPCNIC0311 STRAIN.
Coizeau E, Delgado M, Quintana D, Lemos G, Maida C, Soraya P, Yenay D, Dailis V, and Álvarez A.
FINLAY INSTITUTE, HAVANA, CUBA
84: ADVANCES IN THE CHARACTERIZATION OF A BORDETELLA PERTUSSIS DERIVED
PROTEOLIPOSOME AS VACCINE CANDIDATE AGAINST WHOOPING COUGH.
Rodríguez Y, Fernández S, Infante J, Herrera Y, Fernández Y, Fajardo EM, Mandiarote A, Landys M.
FINLAY INSTITUTE, HAVANA, CUBA
WORKSHOP THERAPEUTIC VACCINES
Chairs:
85: EFFICACY AND SAFETY OF NGCGM3/VSSP VACCINE IN ADVANCED BREAST CANCER PATIENTS.
de la Torre A, Pérez K, Vega AM, Durán Y, Álvarez M, Viada C, Sánchez L et al.
CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA.
86: IMMUNOLOGICAL RESPONSE IN UNRESECTABLE III AN SCLC PATIENTS TREATED WITH A
CONCURRENT COMBINATION OF CIMAVAX-EGF AND CHEMOTHERAPY
Alfonso AL, Neninger E, González A, Hernández M, Fernández A, Mazorra Z, Sánchez L et al.
CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA.
87: SURROGATE BIOMARKERS OF CLINICAL RESPONSE IN STAGE IIIB/IV NON-SMALL-CELL LUNG
CANCER PATIENTS TREATED WITH AN EGF-BASED THERAPEUTIC VACCINE AS A SECOND LINE OF
THERAPY.
Popa X, Fuentes K, Viada C, Neninger E, Rodríguez C, González Z, González A et al.
CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA.
88: EXPERIMENTAL STUDIES OF A VACCINE THAT COMBINES RECOMBINANT HUMAN VEGF AS
ANTIGEN AND ALUMINIUM PHOSPHATE.
Pérez L, Morera Y, Bequet-Romero M, Ramses Hernández G, Rodríguez Y, Castro J, Puente P, Ayala M
and Gavilondo J V.
CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA
89: ENDOGENOUS POLYCLONAL ANTIBODIES GENERATED BY IMMUNIZA-TION WITH
EXTRACELLULAR DOMAINS OF HER1 AND HER2 DECREASE ACTI-VATION AND EXPRESSION OF
HER1 AND HER2 IN TUMOR CELLS INDUCING PRO-APOPTOTIC EFFECTS ONGENE ADDICTION: A
GOOD REASON FOR DESIGNING THERAPIES BASED ON HER1 AND HER2
González N, Bergado G, Hernández DR, Chao L, and Sánchez B.
CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA.
47
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
90: SAFETY, PHARMACOKINETIC EVALUATION AND EFFICACY SIGNS OF INTRAVENOUS CIGB-300
IN PATIENTS WITH SOLID TUMORS, REFRACTORY TO ONCOSPECIFIC TREATMENTS
González Lidia, Noyde B, Soriano J, García R, Ugando E.
Hospital Hermanos Ameijeiras
91: IMMUNOGENICITY OF PARTICLES ADJUVANTS AIF/PI IN THE CANCER VACCINE CANDIDATE
ECD-MEGFR/AIF-PI
Fuentes F, Junco J, Calzada L, Baladrón I, Pimentel E, Basulto R, Reyes O et al.
CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA
92: ANTI-TUMOR EFFECTS OF RACOTUMOMAB VACCINE COMBINED WITH LOW DOSE
CYCLOPHOSPHAMIDE OVERCOME THE DELETERIOUS CONSEQUENCES OF AGING IN A BREAST
CANCER MODEL.
Fuentes D, Cabezas A, Beausoleil I, Avellanet J, García A, Fernández A.
TROPICAL MEDICINE INSTITUTE «PEDRO KOURÍ» (IPK), HAVANA, CUBA
93: IMMUNE RESPONSE IN LONG-TERM NSCLC SURVIVORS TREATED WITH AN EGF-BASED
VACCINE.
Saavedra D, Aguilar Y, Alfonso AL, González A, Mazorra Z, Lorenzo P, Sánchez L, Viada C et al.
CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA.
94: DEVELOPMENT OF AN ANTI-IL-15 VACCINE
Rodríguez Y, Silva R, Gerónimo H, Arrieta C, Hardy E, Castro J, Morera Y, Rodríguez A, Martínez
Moro AR, Perea S, Guillen G, Santos A.
CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA
95: MONOCLONAL ANTIBODIES: ANANALYTICALTOOL IN VACCINE DEVELOPMENT
González E, Otero O, Ramírez F, Reyes F, Camacho F, Fajardo A, Amín N et al.
CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA.
96: IMPACT OF N-GLYCOSYLATION OF THE ANTI-IDIOTYPIC MONOCLONAL
ANTIBODYRACOTUMOMAB IN BIOLOGICALACTIVITY OF VAXIRA VACCINE
Aguilar Y, Rabasa Y, Fuentes D, De la Luz KR.
CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA.
97: SATISFACTION WITH HEALTH CARE OF CAREGIVERS AND PATIENTS ENROLLED IN CLINICAL
TRIALS WITH THERAPEUTIC VACCINES AND MONOCLONAL ANTIBODIES FOR THE TREATMENT OF
ADVANCED LUNG CANCER IN 2014. VILLA CLARA
Lorenzo G, Gil P, Castellanos H, Hernández MA, Martín MI, Cabrera AM, Ortiz RA, Bermúdez A.
CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA.
48
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
98: GANGLIOSIDES-BASEDCANCERVACCINES: TOXICOLOGICALASSAYS
Bada AM, Casacó A, Mancebo A, González B, Fuentes D, Hernández O, Arteaga ME, et al.
TROPICAL MEDICINE INSTITUTE «PEDRO KOURÍ» (IPK), HAVANA, CUBA
99: RESULTS OF THE SAFETY EVALUATION OF CANCER VACCINES DEALING WITH NOVEL TARGETS
FOR CANCER IMMUNOTHERAPY
Mancebo A, Bada AM, Casacó A, González B, León A, Arteaga ME, González C, et al.
TROPICAL MEDICINE INSTITUTE «PEDRO KOURÍ» (IPK), HAVANA, CUBA
100: DEVELOPMENT AND PERFORMANCE EVALUATION OF AN ELISA METHOD FOR POTENCY
ESTIMATION OF CIMAVAX-EGF VACCINE.
Solozábal J, Viña L, Gómez T, Baldriche J, González G, Ruiz E, Sánchez F, Ferrer G.
CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA.
101: DETERMINATION OF RESULTS CORRESPONDENCE BETWEEN FINAL AND INTERIM REPORTS
OF CIMAVAXEGF® CLINICAL TRIAL.
Wong L, Rodríguez C, Fernández E.
INSTITUTE OF PHARMACY & FOODS, HAVANA, CUBA
102: ADHERENCE TO THERAPEUTIC CANCER VACCINES IN CLINICAL TRIALS PATIENTS.
Arencibia M, M Cepeda, Saumell A, Cabrera L, Torres O, Carr A et al.
CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA.
103: SAFETY OF NIMOTUZUMAB IN THE TREATMENT OF HEAD AND NECK TUMORS IN ADVANCED
STAGES IN CAMAGUEY
Ramírez M, Margenat A, Infante E, de Quesada L, Alvarez A, Vila L.
Medical University. Camagüey, Cuba
104: IMMUNOGENICITY OF PARTICLES ADJUVANTS AIF/PI IN THE CANCER VACCINE CANDIDATE
ECD-MEGFR/AIF-PI
Tamargo B, Rubio A, Sánchez B, Gutierrez A, Bergado G, Sierra G.
INSTITUTE OF PHARMACY & FOODS, HAVANA, CUBA
105: SELECTION OF ALUMINUM SALT ADJUVANT TO BE USED IN PREPARA-TION OF THERAPEUTIC
PROTEIN CIGB 247-A. ANTIGEN STABILITY EVALUATION
Hernández GR, Aldana R, Padrón S, Expósito N, Izquierdo M, Pérez M, Terrero Y.
CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA
106: IMPACT OF CIMAVAX-EGF VACCINE IN PATIENTS WITH NON–SMALL CELL LUNG CANCER
TREATED IN TWO POLICLINICS OF CAMAGUEY
Valls AR, López N, Rivera T, Rodríguez Z, del Sol T, Sotomayor M, Nodarse G, Reid J.
CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA.
49
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
107: MAKING SENSE OF CLINICAL TRIAL DATA: CORRECTING FOR SWITCHING TO SECOND LINE
TREATMENT IN THE SURVIVAL ANALYSIS.
Sánchez L, Lorenzo-Luaces P, Crombet T.
CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA.
108: VEGF SPECIFIC CELLULAR RESPONSE TO CIGB-247 CANCER THERAPEUTIC VACCINE: FROM
BENCH TO BEDSIDE.
Bequet M, Ayala M, Morera Y, Sánchez J, Echegoyen AY, Pérez L, Gavilondo JV.
CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA.
109: EFFICACY TRIAL OF THE EPIDERMAL GROWTH FACTOR VACCINE CIMAVAX-EGF IN ADVANCED
NON-SMALL-CELL LUNG CANCER.
Rodriguez PC, Xitllaly Popa, Martínez O, Mendoza S, Santiesteban E.
CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA.
110: VACCINATION WITH A MUTATED VARIANT OF HUMAN VASCULAR ENDOTHELIAL GROWTH
FACTOR BLOCKS VEGF-INDUCED RETINAL NEOVASCULARIZATION IN A EXPERIMENTAL MODEL
Morera Y, González R, Lamdan H, Pérez L, González Y, Agüero J, Castro J, Romero JC et al.
CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA.
111: IMMUNOLOGICAL AND CLINICAL RESULTS OBTAINED IN CASTRATION-RESISTANT PROSTATE
CANCER PATIENTS TREATED WITH AN EGFR-BASED VACCINE
Lavastida A, Aira LE, Popa X, González Z, Mesa M, González Narjara, Bergado G et al.
CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA.
112: IDENTIFICATION AND CHARACTERIZATION OF LONG TERM SURVIVAL POPULATION IN NONSMALL CELL LUNG CANCER PATIENTS TREATED WITH IMMUNOTHERAPIES.
Lorenzo P, Sánchez L, Viada C, Rodríguez C, Álvarez M, Fonte C, Muchene L, Shkedy Z, Lage A.
CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA.
STBV: SYMPOSIUM TUBERCULOSIS VACCINES
Chairs: Nadine Álvarez and Yanelis Tirado
113: FORMULATION OF LIPID-BASED PREPARATION FOR IMMUNOTHERAPY
Morales Y, García M, Casanova M, Hdez M, Medina R, Sifontes S, Nieto L et al.
CHEMICAL BIOACTIVES CENTER, VILLA CLARA, CUBA.
114: PNEUMONIA AS TB LUNG SHAPE (PRESENTATION OF TWO CASES)
Barreiro B, Ramos LT.
Pediatric Hospital Willian Soler
50
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
115: EVALUATION OF THE PROTECTIVE CAPABILITY OF A LIPID EXTRACT DERIVED FROM M.
SMEGMATIS IN A MURINE MODEL OF PROGRESSIVE PULMONARY TUBERCULOSIS.
MA. García, R. Borrero, ME. Lanio, Y. Tirado, N. Álvarez, A. Puig, A. Aguilar et al.
FINLAY INSTITUTE, HAVANA, CUBA
116: DIFFERENTIAL INDUCTION OF SEVERAL CYTOKINES OF RELEVANCE IN TUBERCULOSIS BY
CELLS AND CORD FACTOR OF MYCOBACTERIUM SIMIAE, INCLUDING THE IMMUNOGENIC STRAIN
‘HABANA’ TMC 5135
Mederos LM, Linares C , Bernabéu A , Valero-Guillén PL.
TROPICAL MEDICINE INSTITUTE «PEDRO KOURÍ» (IPK), HAVANA, CUBA
117: ANAL TUBERCULOSIS IN AIDS PATIENT: FIRST CUBAN REPORT.
Mederos LM, Fleites G, Sardiñas, García G, Martínez MR, Díaz R.
TROPICAL MEDICINE INSTITUTE «PEDRO KOURÍ» (IPK), HAVANA, CUBA
118: SURVEILLANCE OF ANTITUBERCULOSISDRUGRESISTANCE IN CUBA, 2010-2014
Lemus D, Echemendía M, Díaz R, Llanes MJ, Suárez L, Marrero A.
TROPICAL MEDICINE INSTITUTE «PEDRO KOURÍ» (IPK), HAVANA, CUBA
SBP: SYMPOSIUM BIOPROCESSES
Chairs: Katia R. de la Luz (CIM) y Ivonne Rodríguez (CIGB)
119: CURRENT TRENDS IN THE VACCINES FIELD. MAIN APPROACHES AT THE FINLAY INSTITUTE.
Hernández J, Utria I, Guzmán M, Crespo Y, Ochoa R, Fernández S, Pérez R et al.
FINLAY INSTITUTE, HAVANA, CUBA
120: THE ANNUAL PRODUCT REVIEW AS A TOOL FOR REAL-TIME VALIDATION IN THE PRODUCTION
OF HEPATITIS B SURFACE ANTIGEN.
Rodríguez I, Rivera J, Madruga Y, Fernández R, De la Torre Y, Suárez G, Martínez C, Hernández.
CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA
121: IMPROVING THE QUALITY AND CONTROL OF THE KINETIC ENDOTOXIN ASSAY (LAL)
Viña L, Rodríguez AG, Vigil L, Girón M, Madera L, Gómez T, Martin L.
CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA.
122: DOCUMENT MANAGEMENT SYSTEM IN THE DEVELOPMENT PHASE,
Apezteguía I, Diago D, González T, González N, Rodríguez E, Santana H, García C, Páez R.
CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA
51
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
123: VALIDATION OF A SANDWICH ELISA FOR THE IDENTITY OF CARBOHYDRATE AND CARRIER
PROTEIN IN MONOVALENT CONJUGATES AND FINAL PRODUCT OF QUIMIVIO VACCINE.
Martínez D, Rodríguez L, Serrano Y, Sánchez H, García N, García-Rivera D.
FINLAY INSTITUTE, HAVANA, CUBA
124: INCREASE THE CELLULAR CONCENTRATION OF MAMMALIAN CELL CULTURE IN BIOREACTORS
STIRRED TANK IN MODE PERFUSION, TO INDUSTRIAL SCALE.
Borrego Y, Ojito E, Chico E, Rodríguez R, Núñez J.
CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA.
125: RESEARH OF DEVIATIONS IN THE RHEGF-RP64K CHEMICAL CONJUGATION PROCESS
González G, Viña L, Peña V, Quintana Y, Castro D, Amaro D.
CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA.
126: RHEUMATOID ARTHRITIS DIAGNOSIS: DEVELOPMENT OF A POLYSTYRENE LATEX-BASED
REAGENT FOR RHEUMATOID FACTOR DETECTION
Marrero G, Delgado LP, Carol H, Ortiz N, Musacchio A and Menéndez T.
BIOMATERIALS CENTER (BIOMAT), HAVANA, CUBA.
127: NMR, OPPORTUNITIES FOR QUALITY CONTROL OF INTERMEDIATES ON CARBOHYDRATE-BASED
VACCINES
Garrido R, Vélez H, Vérez V.
FINLAY INSTITUTE, HAVANA, CUBA
128: CHARACTERIZATION OF VI POLYSACCHARIDE-TETANUS TOXOID CONJUGATE BATCHES OBTAINED
AT PILOT SCALE
Ramírez U, Arias D, Garrido R, Baró B, Pedroso J, Aliaga I, Espinosa C, Villar A.
FINLAY INSTITUTE, HAVANA, CUBA
129: DEVELOPMENT OF AN ANTI-IDIOTYPIC MAB AS CANCER VACCINE: FROM DISCOVERY TO
APPROVAL
de la Luz K, Santo-Tomás J, Aguilar Y, Morales O, Fuentes D, Vidal D, Rabasa Y et al.
CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA.
130: ASSESSMENT THE IMPACT OF MANUFACTURING CHANGES ON HER1-ECD CHARACTERISTICS
(PHYSIC-CHEMICAL AND BIOLOGICAL) DURING THE VACCINE DEVELOPMENT
García K, Prieto Y, Raymond J, Rabasa Y, Sánchez B, Castillo A, and de la Luz K.
CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA.
52
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
131: ISOLATION OF 1E4 IGM ANTI-FASCIOLA HEPATICA
Alba A, Marcet R, Otero O, Hernández HM, Figueredo M, Sarracent J.
TROPICAL MEDICINE INSTITUTE «PEDRO KOURÍ» (IPK), HAVANA, CUBA
132: RESULTS OF THE APPLICATION OF WORK ALGORITHMS FOR THE HEMODERIVADOS
CERTIFICATION AND OTHERS PRODUCTS WITH RISK OF VIRAL CONTAMINATION IN THE YEAR 2014
Romero K, Pérez MT, Blanco M Aguiar Y, Sánchez L, Sánchez E and col.
AIDS RESEARCH LABORATORY, MAYABEQUE, CUBA
133: SYNTHESIS OF POLYSTYRENE LATEX PARTICLES FOR PHARMACEUTICAL APPLICATIONS
Marrero G, Delgado LP, Musacchio A, Menéndez T.
BIOMATERIALS CENTER, HAVANA, CUBA
134: STANDARDIZATION OF AN ELISA FOR DETERMINING HUMAN ANTIBODIES ANTIPOLYSACCHARIDE VI
Álvarez M, Aranguren Y, Fernández S, Rodríguez L.
FINLAY INSTITUTE, HAVANA, CUBA
135: PURIFICATION AND PRELIMINARY CHARACTERIZATION OF OMV DERIVED FROM OUTER
SURFACE OF SALMONELLA PARATYPHY A
Pérez JL, Fernández S, Martínez M, Lescaille D, Serrano D, Blain K, Burguet A.
FINLAY INSTITUTE, HAVANA, CUBA
136: SUSTAINED RELEASE OF BIOLOGICALLY ACTIVE EPIDERMAL GROWTH FACTOR (EGF) FROM
INJECTABLE POLYMERIC MICROSPHERES PROMOTES WOUND HEALING
Cruz E, Caballero L, Aldana R, Berlanga J, Sáez V, Páez R, Castro F.
CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA
137: IN SITU FORMING DRUG DELIVERY SYSTEM FOR THE PARENTERAL CONTROLLED RELEASE OF
RISPERIDONE
Peniche C J, Sáez V, Acosta N, Peniche C A.
BIOMATERIALES CENTER, HAVANA, CUBA
138: BLO T2 ALLERGEN PURIFICATION AND ALLERGENICITY IN ASTHMATIC PATIENTS SENSITIVE TO
BLOMIA TROPICALIS HOUSE DUST MITE
Mateo M, Capote M, Pérez-Llano Y, García A, Cruz R, Luzardo MC, Labrada A.
NATIONAL CENTER OF BIOPRODUCTS (BIOCEN), ARTEMISA, CUBA.
139: EVALUATION OF THE EFFECT OF SILENCING CMAH AND ADAPTATION TO PROTEIN-FREE DIUM
ON THE PROPERTIES OF 14F7 RECOMBINANT MONOCLONAL ANTIBODY.
Morales O, Rabasa Y, Dorvignit D, and de la Luz K.
CENTER OF MOLECULAR IMMUNOLOGY, HAVANA, CUBA.
53
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
WORKSHOP HIV-AIDS
Chairs: Carlos Duarte and Celia Fernández
140: ACUTE TOXICOLOGY OF THE VACCINE CANDIDATE TERAVAC AGAINST THE HIV-1
Bacardí D, Cosme K, Suárez J, Ancizar J, Renault JI, Madrigal R, Romero JC, et al.
CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY, HAVANA, CUBA
141: HIGHLY CONSERVED HIV-1 SUBTYPE B STRAINS REVEALS ANALYSIS OF NEAR FULL-LENGTH
GENOME SEQUENCES OF HIV TYPE 1 IN CUBA.
Blanco M, Machado LY, Martínez O, Noa E, Díaz HM, Romay D, Ruiz N.
AIDS RESEARCH LABORATORY, MAYABEQUE, CUBA
142: CD4+ T-LYMPHOCYTES AND VIRAL LOAD IN PATIENTS WITH AIDS DEBUT WHO RECEIVE
ANTIRETROVIRAL TREATMENT.
Hernández D, Pérez J, Carr A.
TROPICAL MEDICINE INSTITUTE «PEDRO KOURÍ» (IPK), HAVANA, CUBA
143: PHYLODINAMIC OF HIV-1 SUBTYPE B IN CUBA
Machado LY, Martínez O, Díaz HM, Blanco M, Romay D, Dubed M, Silva E.
AIDS RESEARCH LABORATORY, MAYABEQUE, CUBA
144: EVALUATION OF REDOX STATUS IN PATIENTS WITH KAPOSI’S SARCOMA-AIDS.
Duque M, Calás V, Cárdenas A, Leal M, Ugarte Y, Gravier R, Gil L, Jiménez N.
TROPICAL MEDICINE INSTITUTE «PEDRO KOURÍ» (IPK), HAVANA, CUBA
145: THE DIAGNOSIS OF HIV IN CUBA, ROLE OF NATIONAL LABORATORY REFERENCE IN THE
NATIONAL PROGRAM FOR PREVENTION AND CONTROL OF STI / HIV / AIDS.
Silva E, Pérez MT, Díaz H, Romero K, Nibot C, Valdés N, Hernández M.
AIDS RESEARCH LABORATORY, MAYABEQUE, CUBA.
146: COLLOIDAL GOLD NANOPARTICLES CONJUGATION TO BIOMOLECULES OF INTEREST TO
DIAGNOSE INFECTIOUS DISEASES.
Cruz Y, Díaz D. F, Cruz O, Fragas A, Montano L.
AIDS RESEARCH LABORATORY, MAYABEQUE, CUBA
147: SURVEILLANCE OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 TRANSMITTED DRUG
RESISTANCE IN CUBA: IMPORTANT TOOL FOR DESIGN OF NEW THERAPEUTIC STRATEGIES.
Machado LY, Díaz HM , Dubed M , Blanco M , Ruiz N , Romay D , Valdés N et al.
AIDS RESEARCH LABORATORY, MAYABEQUE, CUBA
54
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
Symposium Veterinary Vaccines
Chairs: Deybis Orta
148: METASERVER FOR IN SILICO IDENTIFICATION OF BACTERIAL TARGETS WITH DIAGNOSTIC AND/
OR VACCINE VALUE
Abreu Y, Estévez Y, Bultet L, Rodríguez Y, Agüero JA
NATIONAL CENTRE FOR ANIMAL AND PLANT HEALTH (CENSA). MAYABEQUE, CUBA
149: HOMOLOGATION STUDY OF NEW ADJUVANT MONTANIDE ISA 50 V2 AND THE OILY PHASE OF
GAVAC® IMMUNOGEN
Pérez C, González N, Moreira A, Zamora J.
Centre for Genetic Engineering and Biotechnology, Camagüey, Cuba.
150: PHYSICAL-CHEMICAL CHARACTERIZATION AND COMPARISON THE OILY PHASE OF THE GAVAC®
IMMUNOGEN AND MONTANIDE ISA 50 V2 ADJUVANT. QUALITY EVALUATION AND STABILITY OF
THE FORMED EMULSIONS.
Pérez C, Bricaud M, González N, Gaucheron J.
Centre for Genetic Engineering and Biotechnology, Camagüey, Cuba.
151: ASSESSMENT OF PRECLINIC TOXICITY OF BIVALENT NON-CELLULAR VACCINE AGAINST
LEPTOSPIRA SPP SEROVARS OF VETERINARY EPIDEMIOLOGY INTEREST FOR CUBA
Arencibia DF, Rosario LA, Tamargo B, Infante JF, Batista N.
FINLAY INSTITUTE, HAVANA, CUBA
POSTERS SESSIONS
Thursday 18 (15:00-18:00)
Workshop Immunopharmacology
Chairs: Brizaida Oliva/Darel Martinez (Cuba)
IP-01: PROINFLAMATORY SOLUBLE INTERLEUKIN-15 RECEPTOR ALPHA IS INCREASED IN RHEUMATOID
ARTHRITIS AND IT´S INHIBITED FOR IL-15 ANTAGONIST PEPTIDE.
Santos A, Chico A, Machado A.C., Rodríguez Y, Reyes O, Cabrales A, Gerónimo H, Garay H, Estévez M,
Guillen G.
Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba
55
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
IP-02: CYTOPLASMIC P27KIP1 PREDICTS EARLY RELAPSE IN PATIENTS WITH INVASIVE DUCTAL BREAST
CANCER.
Blanco D, Gutiérrez Z, Jiménez J, Rubio MC, Rodríguez R, Pérez I, Sánchez I, Valdés Z, Martín LF, Camacho
R, Sánchez L, Casanella O, Terry A, Frontela M, Moro A
Instituto de Oncología y Radiobiología (INOR), Havana, Cuba
IP-03: ENHANCED PHARMACODYNAMIC PROPERTIES OF A NOVEL FORMULATION CONTAINING A
SYNERGISTIC MIXTURE OF INTERFERONS ALPHA-2B AND GAMMA IN NON-CLINICAL AND CLINICAL
CONTEXT
García-García I, Díaz-Machado A, González-Delgado C, Tuero-Iglesias A, Pérez-Rodríguez S, GarcíaVega Y, Campos-Mojena R, Cruz-Ramírez A, Castro-Velazco J, Martín-Trujillo A, Santana-Milián H,
López-Saura P, Bello-Rivero I.
Center for Genetic Engineering and Biotechnology CIGB), Havana, Cuba
IP-04: ANTITUMOR EFFICACY, PHARMACOKINETIC AND BIODISTRIBUTION STUDIES OF THE
ANTICANCER PEPTIDE CIGB-552 IN MOUSE MODELS
Vallespí, MG, Pimentel G, Cabrales-Rico A, Garza J, Oliva B, Mendoza O, Gómez Y, Basaco T, Sánchez I,
Calderón C, Rodríguez JC, Markelova M, Fichtner I, Astrada S, Bollati-Fogolín M, Garay E and Reyes O.
Center of Genetics Engineering and Biochtecnology (CIGB), Havana, Cuba.
IP-05: PHARMACOLOGIC INHIBITION OF CASEIN KINASE 2 (CK2)-MEDIATED PHOSPHORYLATION TO
INDUCE CELL DEATH IN ACUTE MYELOID LEUKEMIA CELLS
Cruz Y, Perera Y, Ramos Y, Nuñez T, Cruz LD, González LJ, Perea SE
National Institute of Oncology and Radiobiology (INOR), Havana, Cuba.
IP-06: DIABETES AND ULCERATIVE COLITIS, EVALUATION OF EPIDERMAL GROWTH FACTOR PELLETS
IN ULCERATIVE COLITIS BIOMODEL IN RATS
Aguilera A, Bermúdez Y, Martínez E, Cosme C, Ancizar JA, Bacardí D, Suárez J, Romero JC, Brown E,
Blanco A, Madrigal R, Gorovaya L, Valdes AM, Ferrera A, Martínez L, Urquiza D, Rodríguez Y, Soria Y,
Berlanga J, Páez R.
Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba.
IP-07: THE POPULATION APPROACH TO EVALUATE THE PHARMACOKINETIC AND PHARMACODINAMIC
FOR THREE DOSES OF HEBERPROT-P (25 µG, 75 µG AND 225 µG) COMBINING THE RESULTS OF TWO
CLINICAL TRIALS. SIMULATION OF NON EVALUATED SCENARIOS
Valenzuela C, Hernández I, López P, Pentón G, Cruz A, Campos R, Cervantes M, del Río M, Bataille A,
Herrera A, Rojas D, Brea Y, Hernández R, Baldomero J, Muzio V, Díaz A, Pérez S, Martín A, David M,
Rivero I, Tamayo M, Alvarez M, Barrero L, Reynaldo D, Savigne W, Castillo S y González C. Center for
Genetic Engineering and Biotechnology (CIGB), Havana, Cuba.
56
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
IP-08: EFFECT AND SAFETELY OF THE ADMINISTRATION CONCOMITANT OF THE PEPTIDE CIGB-300
WITH STANDRAD CHEMPRADIOTHERAPY REGIMEN IN PATIENTS WITH CERVICAL STAGE IB2/II.
I BALADRÓN (1), L. GONZALEZ (1), L ESTEVEZ (2), G.CRESPO (3),K GONZÁLEZ (4),J SERRET(5) JA ALVAREZ
(6) A. TUERO (1), C. VALENZUELA (1), S. PEREA (7), B. ACEVEDO (8), Y. ROSALES (1), MD CASTRO (1), K
CATASUS (1), P. LOPEZ (1), FOR THE CERVICONC-300 GROUP*.
Genetic Engineering and Biotechnology (CIGB), Havana, Cuba.
IP-09: CHARACTERIZING FINE EPITOPE SPECIFCITY OF THE THERAPEUTIC ANTIBODY NIMOTUZUMAB:
BIOLOGICAL IMPLICATIONS
Tundidor Y, García C, Pupo A, Cabrera Y and Rojas G.
Center of Molecular Immunology (CIM), Havana, Cuba.
IP-10: SAFETY, PHARMACOKINETIC EVALUATION AND EFFICACY SIGNS OF INTRAVENOUS CIGB-300
IN PATIENTS WITH SOLID TUMORS, REFRACTORY TO ONCOSPECIFIC TREATMENTS
González L, Noyde B., Soriano J., García R., Ugando E., Reyes V., Méndez L., Raíces I , Valenzuela C.
Álvarez L., Fernández E, Perera Y.1, Martin Y., de la Torre A., de la Torre J., Catalá M., Izquierdo M.
García I., Rosales Y., López P., Alonso D., Gómez R., Acevedo B., Perea SE., Muzio VL., TS-300 group.
Genetic Engineering and Biotechnology (CIGB), Havana, Cuba.
IP-11: CELL DEATH AND IMMUNOGENICITY INDUCED BY NIMOTUZUMAB
Lisset Chao, Ailem Rabasa, Greta Garrido, Gretchen Bergado, Cristina Garrido, Federico Garrido, Angel
Miguel García-Lora, Douglas Green, Belinda Sánchez
Center of Molecular Immunology (CIM), Havana, Cuba.
IP-12: PEG-Heberon®, IN COMBINATION WITH RIBAVIRIN IN THE TREATMENT OF CHRONIC HEPATITIS
C IN CUBA. RESULTS FROM INTRODUCTION INTO NATIONAL HEALTH SYSTEM.
Nodarse H, Raices I, Castellanos M, Dorta Z, Arus E, Samada M, Barroso L, Mas M, Velbes P, Nancy R,
Blanco M, Valenzuela C, Lopez P, Campos R, Paez R, Castro F, Muzio V.
Genetic Engineering and Biotechnology (CIGB), Havana, Cuba.
IP-13: META-ANALYSIS OF SAFETY AND EFFICACY IN PATIENTS WITH DIABETIC FOOT ULCERS.
INTERNATIONAL PROYECTION OF HEBERPROT-P®.
Tuero A, González O, Valenzuela C, Alonso M, Baldomero J, Sauri J, del Río A, López P, Yera I, García E,
Muzio V, Rodríguez A, Silva R, Raices M, Hernández A.
Genetic Engineering and Biotechnology (CIGB), Havana, Cuba.
IP-14: EFFECT ON B CELLS AND PHARMACOKINETICS OF AN ANTI-CD20 MONOCLONAL ANTIBODY IN
PATIENTS WITH NON-HODGKIN’S LYMPHOMA: PRELIMINARY RESULTS.
Aguilar Y, Alfonso AL, Aira LE, Lavastida A, Hernández P, Solazabal J, Cepero K, Hernández C, Hernández
C, Cristo V and Mazorra Z.
Center of Molecular Immunology (CIM), Havana, Cuba.
57
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
IP-15: CHARACTERIZATION OF THE SECURITY PROFILE IN 7 CLINICAL TRIALS USING CIGB-300 DURING
2006-2014.
Raíces I., González L., Tuero A., Yera I., Baladrón I., Valenzuela C., García I., Rosales Y., Martin Y., Solares
M., Fang R., Batista N , Soriano J., de la Torre A., Sarduy M., de la Torre J., Acevedo B., Perera Y., Reyes
V., Perea S., Muzio V., CIGB-300 Group.
Genetic Engineering and Biotechnology (CIGB), Havana, Cuba.
IP-16: QUANTITATION OF THERAPEUTIC PEPTIDE IN HUMAN PLASMA BY USING MASS
SPECTROMETRY: APPLICATION TO PHARMACOKINETIC STUDIES IN CLINICAL TRIALS.
Cabrales-Rico A1, Gil J1, Garay HE, Besada V, Hernández-Bernal F, Berlanga J, Gómez JA, Audain E,
Reyes V, Perera-Negrín Y, Perea SE, Reyes O and González LJ.
Center for Genetic Engineering and Biotechnology, Havana, Cuba.
IP-17: ISOLATION OF A HUMAN NEUTRALIZING ANTIBODY FRAGMENT AGAINST A NOVEL EPITOPE
ON VASCULAR ENDOTHELIAL GROWTH FACTOR.
Lamdan H, Gavilondo J.V, Muñoz Y, Pupo A, Huerta V, Musacchio A, Pérez L, Morera Y, Ayala M, Rojas
G, Balint R.F, Larrick J.W
Center for Genetic Engineering and Biotechnology, Havana, Cuba.
IP-18: DEMONSTRATION OF THE ROLE OF GM3 (NEU5GC) ON THE TUMORIGENICITY OF A MOUSE
LYMPHOCYTIC LEUKEMIA B CELL LINE: VALIDATION OF A TARGET FOR CANCER IMMUNOTHERAPY.
Casadesús A, Fernández-Marrero Y, Clavell M, Gómez J, Hernández T, Moreno E, López-Requena A.
Center of Molecular Immunology (CIM), Havana, Cuba.
IP-19: HEBERPROT-P, HOPE AND A BETTER QUALITY OF LIFE. FULL PRECLINICAL PROGRAM.
Bacardí D, Cosme K, Suárez J, Ancizar J, Renault JI, Madrigal R, Romero JC, Urquiza D, Aldana L,
Martínez H, Berlanga J, López E, Acevedo B, Casado JL, Herrera L.
Center for Genetic Engineering and Biotechnology, Havana, Cuba.
IP-20: STICHOLYSINS, PORE FORMING TOXINS AS IMMUNOMODULATOR FOR ENHANCING CTL
MEDIATED IMMUNE RESPONS
Laborde R, Fernández A, Cruz-Leal Y, Oliver L, Luzardo MC, Mesa C, del Valle A, Álvarez C, Alonso ME,
Abreu-Butin L, Longo-Maugéri I, Fernández LE and Lanio ME.
Center for Protein Studies and Department of Biochemistry, Havana University, Cuba.
IP-21: HIGH THROUGHPUT FUNCTIONAL EPITOPE MAPPING: REVISITING PHAGE DISPLAY PLATFORM
TO SCAN TARGET ANTIGEN SURFACE
Infante YC, Tundidor Y, Rojas G.
Center of Molecular Immunology, Havana, Cuba.
58
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
IP-22: STICHOLYSINS, PORE-FORMING TOXINS ENHANCE THE ANTIGEN CROSS- PRESENTATION: A
COMPARISON WITH LISTERIOLYSIN O
Cruz-Leal Y, Laborde R, Viana CS, Grubaugha D, Fernández A, Oliver L, Mesa C, Escalona F, Álvarez C,
Higgins D, Fernández LE and Lanio ME.
Center for Protein Studies and Department of Biochemistry, Havana University, Cuba.
IP-23: EVALUATION OF SAFETY AND THERAPEUTIC EFFECT OF ITOLIZUMAB IN PATIENTS WITH SEVERE
PSORIASIS.
Marrero Y, López I , Mantecón B, Gómez Y, Cardoso Ll.
Manuel Ascunce Domenech» General Teaching Hospital. Camagüey. Cuba.
IP-24: ISOLATION AND PRELIMINAR CARACTERIZATION OF NATURAL-LIKE MONOCLONAL ANTIBODIES
REACTIVE TO A TUMOR-ASSOCIATED GANGLIOSIDE
Nely Rodríguez, Rabade-Chediak M. , Martínez D., Griñán T, Rondón T, Hernández AM.
Center of Molecular Immunology, Havana, Cuba.
IP-25: ANTITUMORAL EFFECT OF STICHOLYSIN II, A PORE FORMING PROTEIN, ON TUMORAL CELLS
IN VITRO AND IN VIVO
Soto C, Del Valle A, Blanco R, Bencomo A, Griñan A, González A, Rodríguez J.C, Viera J, Lanio M1,
Álvarez C, Hernandez A.M.
Center of Molecular Immunology, Havana, Cuba.
IP-26: ANTITUMOR EFFECT OF GM3-CONTAINING NANOPARTICLES-BASED VACCINES ON MICE UNDER
BOTH, LEUKOPENIC CONDITIONS AND IMMUNOSUPPRESSED BY THE PRESENCE OF A TUMOR.
Oliver L1, Fernández A, Raymond J, Fernández LE, Mesa C.
Center of Molecular Immunology, Havana, Cuba.
IP-27: PROGNOSTIC ROLE OF LOCAL IMMUNE INFILTRATE IN PATIENTS WITH COLON CANCER
Calvo A, Lahera T, Torres G, Rengifo CE, de Armas MC, Quintero S, Danta D, Vázquez JM and Escobar X.
Department of Cell Biology and Tissues Banking, National Institute of Oncology, Havana, Cuba.
IP-28: HUMAN MONOCLONAL ANTIBODIES ISOLATED FROM CANCER PATIENTS RECOGNIZE TUMOR
CELLS
Tania Griñán, Hernández AM.
Center of Molecular Immunology (CIM), Havana, Cuba.
IP-29: N-GLYCANS BEARING SLEX EPITOPE AS GLYCOMARKER OF PROSTATE CANCER PROGRESION IN
PATIENTS TREATED WITH HEBERPROVAC
Cabrera G, González-Hernández A, Enríquez Y, Montesino R, Triguero A, Fuentes F, Calzada L, Junco J.
Center for Genetic Engineering and Biotechnology, Havana, Cuba.
59
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
IP-30: POTENTIAL BIOMARKERS IN PATIENTS WITH CERVICAL CANCER STAGE IB2/II TREATED WITH
CIGB-300.
Reyes V, Perera Y, Ancizar J, Suarez J, García I, Valenzuela C, Baladrón I, Solares AM, Sarduy MR,
Alonso D, Gómez D, López-Saura P, Perea S.
Center for Genetic Engineering and Biotechnology, Havana, Cuba.
IP-31: EVALUATION OF INTRAVENOUS CIGB-300 IN PATIENTS REFRACTORY TO ONCOSPECIFIC
TREATMENTS WITH SOLID TUMORS. PHASE I CLINICAL TRIALS
Noyde B., Soriano J., Lima M, Neninger E, Caballero I, García R., Ugando E., Cáceres H., González L.
Reyes V., Méndez L., Raices I., Valenzuela C. Álvarez L., Fernández E., Perera Y., Martin Y., de la Torre A.,
de la Torre J., Catalá M., Izquierdo M. García I. Rosales Y., López P., Alonso D., Gómez R., Acevedo B.,
Perea SE., Muzio VL., TS-300 group.
Oncology Department, Hermanos Ameijeiras Hospital, Havana, Cuba.
IP-32: PHARMACOMETRIC APPROACH TO SUPPORT DOSING STRATEGY OF NIMOTUZUMAB IN
PATIENTS WITH ADVANCED BREAST CANCER.
Rodríguez L., Ramos M., Fernández E., Soriano J., Peraire C., Castañeda G., Jacobo C., de Castro N.
and Colom H.
Laboratory of Pharmacokinetic, Department of Pharmacology & Clinical Pharmacy, Institute of
Pharmacy & Foods, Havana, Cuba.
IP-33: CYTOKINE PATTERN INDUCED BY CRYPTOCOCCUS NEOFORMANS AND CRYPTOCOCCUS GATTII
SPECIES COMPLEX
Illnait-Zaragozí MT, Schoffelen T, Meis JF, Martínez G, Fernández C, Perurena M, Sprong T, Netea MG.
Instituto de Medicina Tropical Pedro Kourí; Havana, Cuba.
IP-34: DIAGNOSIS OF RHEUMATIC DISEASES AUTOINMUMNES THROUGH RHEUMATOID FACTOR IN
THE GENERAL HOSPITAL OF BENGUELA, ANGOLA.
Cardosa E, Aguilar I.
Universidad de Ciencias Médicas Guantánamo, Cuba.
IP-35: INFLAMATORY TUMORS IN THE CENTRAL NERVOUS SYSTEM. CASE REPORT
Vaquer JE, Morales Y.
Arnaldo Milián Castro Hospital, Villa Clara, Cuba.
IP-36: SAFETY NIMOTUZUMAB IN THE TREATMENT OF HEAD AND NECK TUMORS IN ADVANCED
STAGES IN CAMAGUEY
Ramírez M, Margenat A, Infante E, de Quesada L, Álvarez A, Vila L.
CPEC. Medical University. Camagüey.
60
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
IP-37: EFFECTIVENESS AND SAFETY ASSESSMENT OF HEBERPAG USE IN BASOCELLULAR CARCINOMA
PATIENTS
Batista K, Pérez E, Guerra O, Bello I, Patino Y
Mario Gutiérrez Ardaya Clinical. Holguín. Cuba.
IP-38: ANAPHYLAXIS TO ANTIMICROBIAL DRUG. CUBA, 2003-2014
Alfonso I, Jiménez G.
National Centre for State Quality Control of Drugs, (CECMED, Havana, Cuba.
IP-39: PHARMACOKINETICS AND PHARMACODYNAMICS OF PEGYLATED RECOMBINANT HUMAN
ERYTHROPOIETIN (EPOFX1) IN RABBITS.
Reynaldo G, Solozábal J, Becquer M, Colom Y, Gill A, Amaro D and Fernández E
Department of Pharmacology & Clinical Pharmacy, Institute of Pharmacy & Foods. University of
Havana, Havana, Cuba.
IP-40: OPEN STUDY, PERILESIONAL AND INTRALESIONAL APPLICATION OF CIGB-128 (HEBERPAG) IN
CUTANEOUS SQUAMOUS CELL CARCINOMA, STAGE I AND II». PRELIMINARY FINDINGS.
Duncan Roberts Y, Álvarez Escobar PA, Salazar Sedano M, Castro Basart N, Arteaga Hernández E,
Campollo Rodríguez I, Rodríguez Rojas JL, Tuero Iglesias A, García Vega Y, Bello Rivero I.
Center for Genetic Engineering and Biotechnology, Havana, Cuba.
IP-41: PETIVERIA ALLIACEA L HYDRO-ALCOHOLIC CRUDE EXTRACT IN VITRO ACTIVITY IN CANDIDA
CLINIC ISOLATES.
Velar RE, Illnait-Zaragozí MT, Illnait J, Fernández CF, Martínez GF, Perurena MR, Monroy EX,
MeisJFG.
Mycology Laboratory; Tropical Medicine Institute «Pedro Kourí» (IPK), Havana, Cuba.
IP-42: BLOCKING IL-2 SIGNAL IN VIVO WITH AN IL-2 ANTAGONIST REDUCES TUMOUR GROWTH
THROUGH THE CONTROL OF REGULATORY T CELL EXPANSION.
Carmenate T, Ortiz Y, Enamorado M, Graca L, García-Martínez K, León L.
Center of Molecular Immunology, Havana, Cuba.
IP-43: FEASIBILITY EVALUATION AND NEW DESIGN TO DETERMINE SAFETY AND EFFECTIVENESS OF
NIMOTUZUMAB IN ADVANCED ESOPHAGEAL TUMORS OF EPITHELIAL ORIGIN
Saumell Y, Viada CE, Santiesteban Y, Arencibia M, Torres O.
Center of Molecular Immunology, Havana, Cuba.
61
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
IP-44: PHARMACOKINETICS EVALUATION OF HUMANIZED MONOCLONAL ANTIBODY ANTI
EPIDERMAL GROWTH FACTOR RECEPTOR NIMOTUZUMAB IN PATIENTS WITH AUTOSOMAL
DOMINANT POLYCYSTIC KIDNEY DISEASE
de Castro N., Rodríguez L., Villegas C., Dávalos J., Bacallao R. and Ramos M
Laboratory of Biopharmaceutics, Department of Pharmacology & Toxicology, Institute of Pharmacy
& Foods, University of Havana, Havana, Cuba.
IP-45: IMMEDIATE RESPONSE OF HORMONAL FUNCTION DURING CIGB-128 PHARMACO-KINETICS.
Valdés, M; Alonso, C.; García, Y.
Hermanos Ameijeiras Hospital, Havana,Cuba.
IP-46: EVALUATION OF AN ANIMAL MODEL FOR THE DETERMINATION OF THE BIOLOGICAL ACTIVITY
OF THE RACOTUMOMAB ANTI-IDIOTIPIC VACCINE
Jay D, Fuentes D, Santo Tomás JF, Acosta E, Soto D, Somoza N, Contreras B, Contreras F, Portillo A,
Vázquez AM.
National Center for Laboratory Animals Breeding (CENPALAB), Cuba.
IP-47: LEVELS OF CYTOKINES INDUCED BY CUBAN SCORPION VENOM ROPHALURUS JUNCEUS.
Yglesias A, Díaz-García A, Rodríguez H, Rodríguez L
LABIOFAM, Havana, Cuba.
IP-48: LIPOSOMAL ENCAPSULATION OF HOUSE DUST MITE ALLERGENS AND DEXAMETHASONE
MODULATES ALLERGIC RESPONSE IN A MURINE MODEL OF ASTHMA.
Pérez-Llano Y, Ramírez W, Calcines C, Hechavarría M, Cazanave D, Laborde R, Cruz-Leal Y, Morejón A,
Bourg V, Gómez E, Russo M, Labrada A, Luzardo MC
Center for Protein Studies (CEP), Faculty of Biology, University of Havana. Havana, Cuba.
IP-49: CHARACTERIZATION OF HYPERSENSITIVITY ADVERSE REACTIONS. CUBA 2003-2013.
Jiménez López G, Alfonso Orta I.
National Centre for State Control of Drugs, Equipments and Medical Devices (CECMED), Havana, Cuba.
IP-50: CIGB-300: PRECLINICAL STUDIES IN LUNG CANCER MODELS.
Fernando R. Benavent Acero, Yasser Perera, Silvio E. Perea, Stéfano M. Cirigliano, Alejandro Urtreger,
Daniel F. Alonso, Daniel E. Gomez, Hernán G. Farina.
Laboratory of Molecular Oncology, National University of Quilmes, Buenos Aires. Argentina.
IP-51: EXPRESSION OF MYCOBACTERIUM LEPRAE HSP65 IN TOBACCO AND ITS EFFECTIVENESS AS
AN ORAL TREATMENT IN ADJUVANT-INDUCED ARTHRITIS.
César Rodríguez-Narciso, Mayra Pérez-Tapia, Rosa María Rangel-Cano, Celio L. Silva, Mariana MeckesFisher, Rafael Salgado-Garciglia, Sergio Estrada-Parra, Rodolfo López-Gómez, Iris Estrada-García.
Instituto de Investigaciones Químico-Biológicas, Universidad Michoacana de San Nicolás de Hidalgo,
Michoacán.
62
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
IP-52: PHARMACOKINETICS AND RESIDUES OF AMOXICILLIN AND AMPICILLIN IN MILK OF LACTATING
COWS AND THEIR POSSIBLE INTERACTIONS WITH IMMUNE SYSTEM AFTER INTRAMAMMARY
ADMINISTRATION.
Kowalski C, Burmañczuk A, Zañ R, Pormorska-Mól M, Giorgi M
Sub-Department of Pharmacology, Department of Preclinical Veterinary Sciences Faculty of Veterinary
Medicine, University of Life Sciences, Poland.
IP-53: IMMUNOMODULATORY PROPERTIES OF ALLICIN IN MURINE LYMPHOMA.
Padilla I, Martínez M, Lazcano E, Gutiérrez Y.
Centro de investigación y Asistencia en Tecnología y Diseño del Estado de Jalisco, México.
IP-54: ORAL ADMINISTRATION OF CRY1AC TOXIN INDUCE EFFECTS RELATED TO THE INTESTINAL
ALLERGY AND LYMPHOID INTESTINAL HYPERPLASIA.
Santos K.I, Ilhucatzi D, Moreno L.,
Universidad Nacional Autónoma de México, Facultad de Estudios superiores Iztacala, Doctorado en
Ciencias Biomédicas, Tlalnepantla, México.
IP-55: EFFECTIVENESS AND SAFETY ASSESSMENT OF HEBERON USE IN BASOCELLULAR CARCINOMA
PATIENTS
Pérez E, Batista K, Guerra O, Bello I, Plutin Y
Mariana Grajales Coello Medical School. Holguín, Cuba.
IP-56: ANTITUMOR ADJUVANT EFFECT OF THE PROTOXIN Cry1Ac IN A MOUSE MODEL OF BREAST
CANCER.
Servin G. R. R., Ilhuicatzi A. D., Moreno F. L.
Laboratorio 9 Inmunidad en mucosas, UBIMED, Facultad de Estudios Superiores Iztacala, Av. De Los
Barrios 1, 54090 Tlalnepantla, México. Universidad Nacional Autónoma de México.
IP-57: MAKING SENSE OF CLINICAL TRIAL DATA: CORRECTING FOR SWITCHING TO SECOND LINE
TREATMENT IN THE SURVIVAL ANALYSIS.
Sánchez L, Lorenzo-Luaces P, Crombet T
Center of Molecular Immunology, Havana, Cuba.
Workshop of Neuroimmunology
Chairs:
IP-58: EFFECT OF DANCE AS THERAPEUTIC INTERVENTION FOR PATIENTS WITH SPINAL CORD INJURY.
Caren Luciane Bernardi, Maria de Los Angeles Robinson, Regina Biasibetti, Carlos Alberto Gonçalves.
UFRGS. Brazil.
63
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
IP-59: BRAIN HYPOXIA-ISCHEMIA OUTCOMES in rats ARE PREVENTED BY
SWIMMING PROTOCOL DURING PREGNANCY
Sanches, E.F.; Carabali, L.E, Tosta A., Rodrigues A., Schmidt, F, Siebert, C., Netto C.A, Wyse A.T.
Department of Biochemistry, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio
Grande do Sul, Porto Alegre, RS, Brazil.
IP-60: A PANEL OF BRAIN DERIVED PROTEINS, INFLAMMATORY AND CELL DAMAGE MARKERS TO
PREDICT SEVERITY OF STROKE AND PROGNOSIS.
González García S, González-Quevedo A, Peña Sánchez M, Fernández Almirall I, Cordero Eiriz A,
Menéndez Saínz MC, Fernández Carriera R.
Institute of Neurology and Neurosurgery. Havana, Cuba.
IP-61: SERUM INTERLEUKIN: 10, 17 AND TNF AND PARKINSON’S DISEASE.
Pavón N, Lorigado L, León R, Álvarez M, Blanco L, Macías L, Pentón G.
Centro Internacional de Restauración (CIREN). Neurológica, Cuba.
IP-62: BEHAVIOURAL CHANGES AND OXIDATIVE STRESS IN ANIMAL MODEL OF AUTISM INDUCED BY
PRENATAL EXPOSURE TO VALPROATE
González Fraguela ME, Nardin P, Bernardi C, Galland F, Vega Hurtado Y, Gonçalves CA and RobinsonAgramonte MA.
International Center for Neurological Restoration (CIREN). Havana. Cuba.
IP-63: MORPHOLOGICAL AND FUNCTIONAL EVALUATION OF A MODEL OF FOCAL CEREBRAL ISCHEMIA
INDUCED BY ENDOTHELIN-1.
León R. Pavón N, Almaguer W, Lorigados L, Estupiñán B, Blanco L, Merceron D, Macías L, Ramírez M,
García A
International Center for Neurological Restoration (CIREN). Havana. Cuba.
IP-64: THE IMMUNOHISTOCHEMISTRY UTILITY IN DIAGNOSIS OF PHARMACORESISTANT FOCAL
EPILEPSY.
Bárbara Estupiñán Díaz, Lourdes Lorigados Pedre, Lilia Morales Chacón, Iván García Maeso, Margarita
Báez Martín, María Eugenia García Navarro, Nelson Quintanal Cordero, Juan E, Bender del Busto,
Isabel Fernández Jiménez.
International Center for Neurological Restoration (CIREN). Havana. Cuba.
IP-65: SOMATOSENSORY EVOKED POTENTIALS IN CHILDREN WITH AUTISTIC SPECTRUM DISORDERS
Ivette Cabrera, Margarita Báez, Lilia Morales, Reynaldo Galvizu, Carlos Maragoto, Héctor Vera, Ma.
de los Ángeles Ortega.
Clinical Neurophysiology Service. International Center for Neurological Restoration (CIREN). Havana,
Cuba.
64
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
IP-66: PRACTICE GUIA FOR THE EVALUATION OF IMMUNE SYSTEM IN FARMACORESISTENT EPILEPSY.
Lorigados L, Pavón N, Serrano T, Robinson MA, Morales L, Rocha L, Orozco S, Asiel López
International Center for Neurological Restoration (CIREN). Havana. Cuba.
IP-67: CEREBROSPINAL FLUID (CSF) PROTEIN ELECTROPHORESIS IN THE INSTITUTE OF NEUROLOGY
AND NEUROSURGERY. MAIN FINDINGS IN 10 000 CSF SAMPLES.
Fernández Carriera R, González-Quevedo A, González García S, Peña Sánchez M, Fernández Almirall I,
Cordero Eiriz A, Menéndez Saínz MC.
Institute of Neurology and Neurosurgery. Havana, Cuba.
IP-68: SENSORY-MOTOR PERFORMANCE AFTER ACUTE GLUTATHIONE
DEPLETION BY L-BUTHIONINE SULFOXIMINE INJECTION INTO SUBSTANTIA NIGRA PARS COMPACTA
Martínez López JG, Díaz-Hung ML, Blanco L, González M, Orta E.
International Center for Neurological Restoration (CIREN), Havana, Cuba.
IP-69: ELECTROENCEPHALOGRAPHS DISCOVERIES AND CHARACTERISTICS OF SLEEPING IN THE CHILD
AUTISM WITHOUT EPILEPSY
Ramos L and Whilby M
Hospital Pediátrico del Cerro, Havana, Cuba.
IP-70: PHARMACOLOGIACAL INTERVENTION WITH RISPERIDONE IN AUTISTIC PATIENTS
Whilby M, Annia Duany Navarro and Leyani Ramos Hernández
Hospital Docente Pediátrico del Cerro, Havana, Cuba.
IP-71: NUTRITION AND IMMUNOLOGICAL PARAMETERS IN THE REHABILITATION OF SPINAL CORD
TRAUMA
Zamora F, González C, Hernández E, Díaz A, Álvarez C.
International Center for Neurological Restoration (CIREN), Havana, Cuba.
IP-72: INFLUENCE OF PHYSICAL REHABILITATION IN THE IMMUNE RESPONSE OF PATIENTS WITH
SPINAL CORD TRAUMA IN PEDIATRIC AGE.
González C, Zamora F.
International Center for Neurological Restoration (CIREN). Havana. Cuba.
IP-73: NEUROPROTECTION IN A MODEL OF AUTISM TRANSPLANTED WITH BONE MARROW CELLS
Yamile Vega Hurtado, Dunia Lee Mustelier, Esteban Alberti-Amador E, María Elena González Fraguela,
Robinson-Agramonte M A.
International Center for Neurological Restoration (CIREN). Havana. Cuba.
IP-74: SELF-ESTEEM LEVELS IN CUBAN PATIENTS WITH SYSTEMIC ERYTHEMATOSUS LUPUS DIAGNOSIS
María Eugenia Lánigan Gutiérrez.
Hospital Clínico Quirúrgico Joaquín Albarrán. Cuba.
65
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
IP-75: RAPID NON-ENZYMATIC METHOD FOR MOLECULAR TYPING OF SACCHAROMYCES CEREVISIAE
BY PULSED FIELD MINIGEL ELECTOPHORESIS UNI AND BY TWO-DIMENSIONAL.
Santamaría Y, León K, Manrique V, Arencibia O, López-Cánovas L.
Centro de Neurociencias de Cuba.
IP-76: TRAINING PATIENTS WITH MULTIPLE SCLEROSIS FOR USE INTERFERON.
D.Grass Fernández,.J A. Cabrera., A . González Quevedo
International Center for Neurological Restoration (CIREN). Havana. Cuba.
IP-77: NEUROPATHOLOGY, BIOCHEMICAL MARKERS AND DISEASES LYSOSOMAL.
Larrinaga Vicente, Lázara Emma, Acosta Sánchez, Tatiana Menéndez Saínz Mary Caridad, Dialys
Rodríguez Torres, Miranda Romero, Misleidys.
National Genetics Centro Medical / Laboratory of Biochemical Genetics, Havana, Cuba.
IP-78: THE NEUROPROTECTIVE EFFECT OF ERYTHROPOIETIN IN AUTISM MODEL IN RATS.
Becquer María de los Angeles, Adonis Armenteros López, Hurtado Vega Yamile, González Fraguela
María Elena, and María Robinson-Agramonte.
INSTITUTE OF PHARMACY & FOODS, HAVANA, CUBA. Havana University.
IP-79: EFFECT OF NEUROTOXIC LESION OF PEDUNCULOPONTINE NUCLEUS IN NIGRAL AND STRIATAL
REDOX BALANCE AND MOTOR PERFORMANCE IN RATS.
Lisette Blanco, Javier Jiménez, Ma. Elena González, Mei-Li Díaz , Teresa Serrano, Yoel Lacerda, Liliana
Francis.
International Center for Neurological Restoration (CIREN). Havana. Cuba.
IP-80: IN SILICO STUDY OF THE INTERACTION BETWEEN b-AMYLOID PEPTIDE AND NAPHTHALENEDERIVATIVE COMPOUNDS: A FIRST STEP ON THE DISRUPTION OF AMYLOID AGGREGATION.
Bencomo A, Rodríguez-Tanty C, Álvarez-Ginarte Y, Sablón-Carrazana M, Pupo A.
Cuban Neuroscience Center, Havana, Cuba.
IP-81: IFN-γγ AND C-PHYCOCYANIN COMBINATION IN VITRO IMMUNOMODULATORY RESPONSES.
Cervantes-Llanos M, Alonso-Ramírez R, De Feo D, Cabrera Gómez JA, Valenzuela-Silva C, Llópiz Arzuaga
A, Milian Jordan A, Ruffini F, Brambilla E, Martino G,Pentón-Rol G.
Center for Genetic Engineering and Biotechnology (CIGB), Havana, Cuba.
IP-82: VALPROIC ACID AND LAMOTRIGINE EFFECTS IN ELECTRIC CEREBRAL ACTIVITY OF JUVENILE
MYOCLONIC EPILEPSY PATIENTS.
Ivonne Jiménez, Maydelin Alfonso, Raúl Valdez.
International Center for Neurological Restoration (CIREN). Havana. Cuba.
66
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
IP-83: IMPACT OF PLANT DERIVED FLAVONOIDS ON GLIA MODULATION AND NEURODEGENERATIVE
DISEASES.
Souza C.S., Santos, C.C., Borba F., Grangeiro M.S., Silva V.D.A., Costa S.L.
Laboratory of Neurochemistry, Health Sciences Institute, Federal University of Bahia, Brazil.
IP-84: IN VITRO INFECTION OF GLIA/NEURON CO-CULTURES BY NEOSPORA CANINUM: POSSIBLE
ROLES OF INOS, IDO AND COX-2 IN IMMUNO MODULATION.
Santos, A.B.; Arruda, M.R.; Jesus, L.B.; Freitas, S. C. M.; Jesús, E.E.V.; Cunha, E.F.S. and Costa, M.F.D.
Laboratório de Neuroquímica e Biologia Celular-Federal University of BahiaINCT- Instituto Nacional
de Neurociências Translacional/CNPq Brazil.
IP-85: MATERNAL SWIMMING AS A NEUROPROTECTIVE STRATEGY IN A ADHD MODEL USING
SPONTANEOUS HYPERTENSIVE RATS.
Tosta A, Bernardi C, Sanches E, Gonçalves C.A.
Universidad e Federal do Rio Grande do Sul –Porto Alegre/ RS, Brasil.
IP-86: A NOVEL POTENT ANTIOXIDANT, DERIVATIVE ARILIDENMALONATE: CHARACTERIZATION OF
THE NEUROPROTECTIVE PROPERTIES IN VIVO MODELS OF PARKINSON’S DISEASE.
Fonseca Fonseca LA, Núñez Figueredo Y, Ramírez Sánchez J, García Pupo L, Wong Guerra M, Ochoa
Rodríguez E, Verdecia Reyes Y, Amaral da Silva VD, Delgado Hernández R, Lima Costa S.
Centro de Investigación y Desarrollo de Medicamentos, Havana, Cuba.
IP-87: NEUROPROTECTIVE EFFECT OF JM-20, A NOVEL MULTI-TARGET LIGAND, IN DIFFERENT
EXPERIMENTAL MODELS RELATED TO CEREBRAL ISCHEMIA.
Nuñez Y, Ramírez J, Onofre D, Loureiro S, Salbego C, Hansel G, Delgado R, Ochoa E, Verdecia Y, Costa
L, Merino N, Pardo G
Centro de Investigación y Desarrollo de Medicamentos, Havana, Cuba.
IP-88: EFFECT OF JM-20 AGAINST COGNITIVE DEFICITS INDUCED BY SCOPOLAMINE IN RATS.
Wong G, Jiménez J, de Assis A, Onofre D, Delgado R, Ochoa E, Verdecia Y, Fonseca L, Ramírez J, García
L, Pardo G, Núñez Y.
Centro de Investigación y Desarrollo de Medicamentos, Havana, Cuba.
IP-89: DISCERNING THE ANTIOXIDANT MECHANISM OF RAPANONE RELATED TO ITS IRON BINDING
AND ROS SCAVENGING ACTIVITY: A PROMISING THERAPEUTIC APPROACH IN NEURODEGENERATIVE
DISEASES
de la Vega-Hernández K1, FonsecaL2, Núñez-FigueredoY2, Delgado-Hernández R2, AntuchM3, CuestaRubio O4, Pardo-Andreu GL5.
INSTITUTE OF PHARMACY & FOODS, HAVANA, CUBA. Havana University. Havana, Cuba.
67
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
IP-90: NEUROPROTECTOR EFFECTS OF NEURO-EPO IN AMYLOID TOXICITY IN THE Aß 25-35 NONTRANSGENIC MOUSE MODEL OF ALZHEIMER’S DISEASE.
Yamila Rodríguez Cruz, Julio César García Rodríguez; and Nibaldo Hernández Mesa.
Histology Department from Havana Medical School University. Havana, Cuba.
IP-91: IMMUNEREGULATORY PHENOTYPE SHIFT BY BEE APIS ACCUPUNCTURE IN PRIMARY
PROGRESIVE MULTIPLE SCLEROSIS (PPMS).
Abuín A., Fernández F., Milián L., Rodríguez Y.
Matanzas Medical Science Universisty, Cuba.
IP-92: EVALUATION OF THERAPEUTIC EFFECT OF HUMAN MESENCHYMAL STEM CELLS DERIVED FROM
BONE MARROW IN CULTURE IN A MODELS OF FOCAL ISCHEMIC INJURY INDUCED BY
THERMOCOAGULATION.
Lee, Dunia; Almaguer, William; Vega, Yamile; de la Cuétara, Karelys; López, Asiel; Estupiñan, Bárbara;
Fernández, Isabel.
International Center for Neurological Restoration (CIREN), Havana, Cuba.
IP-93: AUTOIMMUNE NEUROPATHIES. PHYSIOPATHOLOGYCAL REVIEW AND
ELECTROPHYSIOLOGYCAL EXPRESSION
Hernández A
Clinical Neurophysiology Department. CCOI «Frank País», Cuba.
IP-94: AUTO ANTIBODIES AGAINS BRAIN ANTIGENS AS ALZHEIMER’S DISEASE BIOMARKERS, EFECT
OF APOE4 ALLELE
Manrique Suárez V, Sosa S, Fernández Y, Urrutia N, Álvarez Y, Cristiá L, Doreste M, Ruiz E, Bobes MA,
Posada A, Rodríguez-Tanty C.
Cuban Neurosciences Center.
Symposium of Atherosclerosis
Chairs:
IP-95: THE INVOLVEMENT OF RGS5 IN THE ANTI-ATHEROSCLEROTIC ACTIVITIES OF RED GINSENG
WATER EXTRACT
Rhee MH, Kim TH
College of Veterinary Medicine, Kyungpook National University, Korea.
IP-96: THERAPEUTIC EFFECT OF chP3R99 MONOCLONAL ANTIBODY AGAINST LIPOFUNDIN-INDUCED
ATHEROSCLEROTIC LESIONS IN RABBITS
Acosta E, Delgado L, Álvarez D, Medina JA, Vera M, Noa M, Bécquer MA, Fernández E, Vázquez AM.
Center for Advanced Study in Cuba (CEAC), Havana, Cuba.
68
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
IP-97: KINETIC OF ANTI-ANTI-IDIOTYPE RESPONSE TO CHONDROITIN SULPHATE IN APOE DEFICIENT
MICE IMMUNIZED WITH CHP3R99 MAB AT DIFFERENT STAGE OF ATHEROSCLEROSIS PROGRESSION
Sarduy R*, Brito V, Soto Y, Griñán T, Viera J, Vázquez AM
Center of Molecular Immunology, Havana, Cuba.
IP-98: THERAPEUTIC IMMUNIZATION WITH AN ANTI-GLYCOSAMINOGLYCAN ANTIBODY REDUCES
ATHEROSCLEROSIS IN MICE BY REGULATING OXIDATIVE STRESS AND INFLAMMATION
Brito V, Delgado-Roche L, Acosta E, Pérez A, Fernández J, Hernández Y, Bécquer MA, Griñán T, Soto Y,
León O.S, Marleau S, Vázquez AM.
Center of Molecular Immunology, Havana, Cuba.
IP-99: TARGETING ARTERIAL WALL SULFATED GLYCOSAMINOGLYCANS IN RABBIT ATHEROSCLEROSIS
WITH A MOUSE/HUMAN CHIMERIC ANTIBODY
Soto Y, Mesa N, Alfonso Y, Pérez A, Batlle F, Griñán T, Pino A, Viera J,
Frómeta M, Brito V, Olivera A, Zayas F and Vázquez AM.
Center of Molecular Immunology, Havana, Cuba.
IP-100: HYPOCHOLESTEROLEMIC AND ANTI-ATHEROSCLEROTIC EFFECTS OF CRUDE LEAF EXTRACT
OF MORINGA OLEIFERA IN APOE KO MICE
Fuentes D, Fernández N, Díaz BL, León A, Blanco D, Gutiérrez M, García A, Ronda M, Prida Y, Torres Y,
Cabezas L.
National Center for Laboratory Animal Breeding (CENPALAB), Havana, Cuba.
IP-101: MONOCLONAL ANTIBODIES WHICH DISCRIMINATE BETWEEN NATIVE AND OXIDIZED LOW
DENSITY LIPOPROTEINS.
Bebelagua Y, Rodríguez KM, Vázquez AM.
Center of Molecular Immunology, Havana, Cuba.
IP-102: USING PERSONALIZED BACH FLOWER THERAPY FOR DIABETIC PATIENTS WITH DYSLIPIDEMIA
Mahía M, Diaz A, Quintela A, Hernández J, Arpajón Y, Llano Y.
National Institute of Angiology and Vascular Surgery, Calzada del Cerro 1551, Cerro, Havana, Cuba.
IP-103: PHYSIOLOGICAL AND PATHOLOGICAL COMPARISON BETWEEN 2, 8 AND 15 MONTH OLD APOE
KO MICE FED WITH NORMAL DIET AS MODEL OF ATHEROSCLEROSIS.
Fernández N, Beausoleil I, Jay D, Díaz BL, Brooks L, León A, García A, Ronda M, Gutiérrez M, Torres Y,
Rodríguez M, Fuentes D
National Center for Laboratory Animal Breeding (CENPALAB), Havana, Cuba.
69
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
IP-104: THE THERAPEUTIC IMMUNIZATION WITH AN ANTI-GLYCOSAMINOGLYCAN ANTIBODY
ATTENUATES OXIDATIVE STRESS IN ATHEROSCLEROTIC RABBITS
Hernández Y 1, Delgado-Roche L2, Dalia R. Álvarez 1, Vázquez AM 3.
Center of Studies for Research and Biological Evaluations, Pharmacy and Food Sciences Institute,
University of Havana, Havana, Cuba.
Symposium of Inflammation and Pain
Chairs:
IP-105: ANTI-INFLAMMATORY EFFECT OF THE ETHANOLIC EXTRACT OF SOLANUM DIPLOCONOS
FLOWERS IN MICE.
Ivonilce Venturi, Livan Delgado-Roche, Ivones Hernández, Angela Malheiros, Idania Rodeiro.
Department of Pharmacology, Center of Marine Bioproducts, Havana, Cuba.
IP-106: ANTI-DIABETIC, ANTIOXIDANT AND ANTI-INFLAMMATORY EFFECTS OF MOMORDICA
CHARANTIA L PLANT EXTRACT.
Bellma A, Lagarto A, Menéndez R, Wong M , Aparicio G, Merino N, Valdés O, López O, Casanave D and
Nogueiras A.
Centro de Investigación y Desarrollo de Medicamentos (CIDEM). Havana, Cuba.
IP-107: COMPARATION OF ANTI-INFLAMMATORY ACTIVITY OF 2-ALKYL AND 2-BENCYL-5NITROINDAZOLINONES
Siverio-Mota D, Andújar I, Marrero-Ponce Y, Giner RM, Vicet-Muro L, Herrera-Pis Y, Cordero-Maldonado
ML, de Witte PAM, Crawford AD, Sylla-Iyarreta-Veitía M, Arán VJ
Unit of Computer-Aided Molecular «Biosilico» Discovery and Bioinformatic Research (CAMD-BIR Unit),
Faculty of Chemistry-Pharmacy, Universidad Central «Marta Abreu» de Las Villas, Villa Clara, Cuba.
IP-108: PERCUTANEOUS ASPIRATION AND OZONO APLICATION INTO LUMBAR FACET JOINT CYSTS
Valdes-Llerena R. Garbey-Fernández R, Gómez-Monduy Y.
Anaesthesiology Neurosurgery Service of International Center for Neurological Restoration (CIREN),
Havana, Cuba.
IP-109: ANTI-INFLAMMATORY EFFECT OF ONE EXTRACT FROM ULVA FASCIATA A MACRO ALGA IN
MICE.
Fernández M.D, Hernández I., Hernández Y., Cuellar C., del Vallin T., Rodeiro I.
Department of Pharmacology, Center of Marine Bioproducts (CEBIMAR), Havana, Cuba.
70
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
Symposium on Pharmacology of Cytochrome P450, transporters and Omics
Chairs:
IP-110: IN VITRO MODULATION OF CYTOCHROME P450 ENZYMES BY CUBAN NATURAL PRODUCTS.
Pérez C.L., Donato M.T., Herrera J.A., Marrero E., González K., Gómez-Lechón M.J., Rodeiro I.
Institute for Basic and Preclinical Sciences ¨Victoria de Girón¨, Havana, Cuba.
IP-111: IN VITRO AND IN VIVO REVERSAL OF P-GLYCOPROTEIN MEDIATED MULTIDRUG RESISTANCE
BY THALASSIA TESTUDINUM EXTRACT, A NATURAL PRODUCT WITH ANTI-TUMOR PROPERTIES.
Hernández I, Rodeiro I, Labrada M., Delgado L., Herrera J.A., Fernández MD, Carr A., Delgado R. ,
Vanden Bergue W., Lopes M.T.
Center of Marine Bioproducts (CEBIMAR), Havana, Cuba.
IP-112: ULVA FASCIATA EXTRACT MODULATES CYTOCHROME P450 ENZYMES ACTIVITY IN RAT
HEPATOCYTES.
Herrera M.E., Pérez C.L., Donato M.T., Hernández I., Herrera J.A., Hernández Y., Gómez-Lechón M. J.,
Rodeiro I.
Department of Pharmacology, Center of Marine Bioactives, Havana, Cuba.
IP-113: ULVA FASCIATA PROTECTS AGAINST GENETIC DAMAGE CAUSED BY BENZO(A)-PIRENE.
Fernández G. 1, Pérez C.L. 1, Hernández Y. 2, Fernández M.D. 2, Rodeiro I.2.
Institute for Basic and Preclinical Sciences ¨Victoria de Girón¨, Havana, Cuba.
IP-114: EFFECTS OF THALASSIA TESTUDINUM EXTRACT ON P450 SYSTEM IN THE LIVER WISTAR RATS:
IMPACT ON THE ELIMINATION OF THEOPHYLLINE AND BIOTRANSFORMATION OF BENZO(A)PIRENE.
Rodeiro I.1, Hernández S.2, Hernández I.1, Padrón S.3, Herrera J.A.4, Olguín S.2, Camacho R.2, Ronquillo
D.2, Menéndez R.3, Fernández M.D.1, Espinosa-Aguirre J.J.2.
Departamento de Farmacología, Centro de Bioproductos Marinos (CEBIMAR), Havana, Cuba.
IP-115: COMMON VARIANTS AT THE 9q22.23, 14q13.3 AND ATM LOCI, AND RISK OF DIFFERENTIATED
THYROID CANCER IN THE CUBAN POPULATION
Pereda C M, Lesueur F, Pertesi M , Robinot N, Lence J, Turcios SE, Velasco M, Chappe M, Infante I,
Bustillo M, García A, Clero E, Xhaard C, Ren Y, MaillardS, Damiola F, Rubino C, Salazar S, Román G,
Rodríguez R, Ortiz RM, De Vathaire F
Institute of Oncology and Radiobiology, Havana, Cuba.
IP-116: KNOWLEDGE ON PHARMACOGENETICS, GENOMICS AND MOLECULAR DIAGNOSTIC
TECHNOLOGIES IN DOCTORS ENTERING MEDICAL RESIDENCIES.
Hernández-Betancourt JC.
Dr. Ernesto Guevara Hospital, Las Tunas, Cuba.
71
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
IP-117: NETWORK ANALYSIS REVEALS THE BENEFITS OF INTERFERON BETA AND C-PHYCOCYANIN
TREATMENT IN AN EXPERIMENTAL MODEL OF AUTOIMMUNE ENCEPHALOMYELITIS IN C57BL6
MICE.
Fernández-Masso JR, Nazabal-Gálvez M, Cervantes-Llanos M, Lagumersindez-Denis N, Llópiz
Arzuaga A, Cintado- Benítez, Pentón-Arias E, Pentón-Rol G.
Center for Genetic Engineering and Biotechnology,Havana,Cuba.
IP-118: GENETIC FACTORS FOR MULTIPLE SCLEROSIS AND NEUROMYELITIS OPTICA IN CUBAN
PATIENTS.
Fernández-de-Cossío ME, Nazabal M, Cintado A, Díaz T, Hanlet C, Villarreal A, Ale M, Grass D, CervantesLlanos M, Pavón-Fuentes N, Benítez JV, Cabrera-Gómez JA, Pentón-Rol G.
Center for Genetic Engineering and Biotechnology, Havana, Cuba.
Symposium Hereditary Ataxias
Chairs:
IP-119: ALTERED REDOX STATUS IN CUBAN PATIENTS WITH SPINOCEREBELLAR ATAXIA TYPE 2
Guevara M, Gil L, Martínez G, Velásquez L.
Biopharmaceutical and chemical Group (LABIOFAM), Havana, Cuba.
Center for Research and Rehabilitation of Hereditary Ataxias (CIRAH), Holguín, Cuba.
IP-120: ROLE OF GLUTATHIONE S-TRANSFERASES IN THE SPINOCEREBELLAR ATAXIA TYPE 2 CLINICAL
PHENOTYPE.
Almaguer-Gotay D1, Almaguer-Mederos LE, Aguilera-Rodríguez R, Estupiñán-Rodríguez A, GonzálezZaldívar Y, Cuello-Almarales D, Laffita-Mesa JM, Vázquez-Mojena Y.
Center for the Research and Rehabilitation of Hereditary Ataxias (CIRAH).
72
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
NOTES
73
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
NOTES
74
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
NOTES
75
IMMUNOPHARMACOLOGY - VACCIPHARMA 2015
NOTES
76